

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 15/19, C12P 21/02 A61K 37/02, C12N 15/11 C07K 13/00, C12N 15/00 C12P 21/08, A01K 67/027	A1	(11) International Publication Number: WO 93/22437 (43) International Publication Date: 11 November 1993 (11.11.93)
---	----	--

(21) International Application Number: PCT/EP93/01022
(22) International Filing Date: 28 April 1993 (28.04.93)

(30) Priority data: 92401231.3 30 April 1992 (30.04.92) EP
(34) Countries for which the regional or international application was filed: GB et al.

(71) Applicant (for all designated States except US): N.V. INNOGENETICS S.A. [BE/BE]; Industriepark, Zwijnaarde 7, Box 4, B-9052 Ghent (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FRANSEN, Lucia [BE/BE]; Nederbosstraat 45, B-9810 Nazareth-Eke (BE). DEVOS, Kathleen [BE/BE]; Schouteerpark 2, B-9070 Destelbergen (BE). VAN DE VOORDE, André [BE/BE]; Groenstraat 22, B-9160 Lokeren (BE). VAN HEUVERS-WYN, Hugo [BE/BE]; Colmanstraat 62, B-9270 Kalken (BE).

(74) Agent: GROSSET-FOURNIER, Chantal; Grosset-Fournier & Demachy s.a.r.l., 103, rue La Fayette, F-75010 Paris (FR).

(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

*With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: NEW POLYPEPTIDES AND PEPTIDES, NUCLEIC ACIDS CODING FOR THEM, AND THEIR USE IN THE FIELD OF TUMOR THERAPY, INFLAMMATION OR IMMUNOLOGY

(57) Abstract

The invention relates: to a polypeptide containing in its peptidic chain the amino acid sequence of 311 amino acids of figure 3, or a fragment of this sequence, with said fragment being such that it is liable to produce antibodies capable of forming a complex with the amino acid sequence of figure 3, or an amino acid sequence having a percentage of homology of at least 50 %, preferably 75 %, and advantageously 90 % with the amino acid sequence of figure 3, and to pharmaceutical compositions containing, as active substance, at least one of the polypeptides of the invention or of the antagonists of the polypeptides of the invention as antitumor compounds, or antiinflammatory compounds or as growth activators of T-cells and B-cells, as bone repair compounds as inducer of immunosuppressive cells, as inhibitors of anti-colony stimulating factor; or as trypanocidal agents; or part of the polypeptides of the invention, capable of binding to the above-defined receptor.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

5 NEW POLYPEPTIDES AND PEPTIDES, NUCLEIC ACIDS CODING FOR THEM, AND THEIR USE IN THE FIELD OF TUMOR THERAPY, INFLAMMATION OR IMMUNOLOGY

10

The invention relates to polypeptides and peptides, particularly recombinant polypeptides, which can be useful in the field of tumor therapy, inflammation or immunology.

15 The invention also relates to a process for preparing the above-said polypeptides and peptides.

It also relates to nucleic acids coding for said polypeptides and peptides.

Monocytes/macrophages are cells of great complexity accomplishing a multitude of different functions related to (i) responses to environmental challenges such as phagocytosis, antigen processing and presentation, (ii) enzyme production, 20 (iii) to differentiation, (iv) to regulatory responses by the synthesis of macrophage-specific cytokines which function as metabolic or immunological regulatory proteins and (v) by the production of complement components, coagulation factors, enzymes, enzyme inhibitors, and oxygen radicals (reviewed by Adams and Hamilton (1984).

25 Several macrophage-derived cytokines have already been described: interleukin-1 (IL-1), tumor necrosis factor (TNF), interleukin-6 (IL-6), colony stimulating factor (CSF), interferon (IFN), macrophage inflammatory protein (MIP), and monocytic-derived neutrophil chemotactic factor (MDNCF or IL-8) (Old, 1985; Durum et al., 1986; Quesenberry, 1986; Billiau, 1987; Yoshimura et al., 1987; Davatellis et al., 1988; Kishimoto and Hirano, 1988;). In most instances, 30 the production of these cytokines by the macrophages requires exposure to one or more signals present in the immediate microenvironment of the cells. These signals may consist of particulate matter which can be opsonized, invading parasites, bacterial infectants, or antibody-covered antigens (Unanue, (1989)). They 35 invariably lead to a state of enhanced competence of the macrophage (termed activation), ultimately giving rise to the synthesis of some of the above-mentioned macrophage-specific cytokines (monokines).

A particular set of genes (some of which are specifically expressed by macrophages, hereafter termed monokine genes) may correspond to each individual 40 activation process. Such genes can either be up- or down-regulated. Characterization of some of these genes is possible by measuring their

2
5 corresponding biological function with appropriate bioassays (Ruff and Gifford, 1986; Van Snick et al., 1986; Van Damme et al., 1987), or using differential

hybridization with cDNAs derived from either activated or nonactivated macrophages. This can result in the isolation of cDNAs that correspond to genes switched on during the process of differentiation of resting macrophages to
10 activated cells.

It is an object of the invention to provide new polypeptides and their corresponding nucleic acids which can be used in immunology or in the field of tumor therapy.

It is another object of the invention to provide nucleic acids coding for the peptide chains of biologically pure, active recombinant peptides which enable their
15 preparation on a large scale.

It is another aspect of the invention to provide nucleic sequences which can be used as antisense oligonucleotides.

It is another aspect of the invention to provide a chromosomal DNA fragment
20 which can be used for producing a pathological model of a nonhuman animal such as a transgenic animal which can be used to study the effects of pharmacological compositions and to prepare different cell types from these transgenic animals which express the gene of the invention in a constitutive or inducible way.

It is another aspect of the invention to provide "knock-out" transgenic animals
25 (Capecchi, 1989) in which the natural gene effectively homologous to the nucleotide sequences of the invention (definition of effectively homologous given hereafter) is rendered nonfunctional, for instance, by homologous recombination, with said animal being suitable for the study of the possible loss of functions or the possible restoration effects caused by the reintroduction of the polypeptides of the
30 invention into the animals.

The polypeptide of the invention is characterized by the fact that it contains in its peptidic chain:

- the amino acid sequence of 311 amino acids of Figure 3,
- or a fragment of this sequence, with said fragment being such that it is liable
35 to produce antibodies capable of forming a complex with the amino acid sequence of Figure 3,

- or an amino acid sequence having a percentage of homology of at least 50%, preferably 75%, and advantageously 90%, with the amino acid sequence of Figure 3,

- 40 - or a sequence liable to form a complex with antibodies raised

- * against the amino acid sequence of Figure 3

- * or against pep1(m)

5 * or against pep2(m)

 * or against pep3(m)

Pep1(m) has at least 8 contiguous amino acids contained in the following sequence:

 Cys⁵²-Ser-Trp-Lys-Gly-Ser-Gly-Leu-Thr-Arg-Glu-Ala-Arg-Ser-Lys-Glu-Val-
10 Glu-Gln-Val-Tyr-Leu-Arg-Cys,

 and preferably is the following sequence:

 Arg-Glu-Ala-Arg-Ser-Lys-Glu-Val-Glu.

Pep2(m) has at least 8 contiguous amino acids contained in the following sequence:

15 Cys¹⁰⁷-Ile-Lys-Pro-Phe-Arg-Asp-Ser-Ser-Gly-Ala-Asn-Ile-Tyr-Leu-Glu-Lys-
Thr-Gly-Glu-Leu-Arg-Leu-Leu-Val-Arg-Asp-Ile-Arg-Gly-Glu-Pro-Gly-Gln-Val-
Gln-Cys,

 and preferably is the following sequence:

 Arg-Asp-Ile-Arg-Gly-Glu.

20 Pep3(m) has at least 8 contiguous amino acids contained in the following sequence:

 Gly²⁸³-Cys-Ala-Pro-Arg-Phe-Ser-Asp-Phe-Gln-Arg-Met-Tyr-Arg-Lys-Ala-
Glu-Glu-Met-Gly-Ile-Asn-Pro-Cys-Glu-Ile-Asn-Met-Glu,

 and preferably is the following sequence:

25 Arg-Lys-Ala-Glu-Glu.

According to another advantageous embodiment of the invention, the peptide contains in its peptidic chain:

- the amino acid sequence of 311 amino acids of Figure 2,

- or a fragment of this sequence, with said fragment being such that it is liable
30 to produce antibodies capable of forming a complex with the amino acid sequence of Figure 2,

- or an amino acid sequence having a percentage of homology of at least 50%, preferably 75%, and advantageously 90%, with the amino acid sequence of Figure 2,

35 - or a sequence liable to form a complex with antibodies raised:

 * against the amino acid sequence of Figure 2

 * or against pep1(h)

 * or against pep2(h)

 * or against pep3(h).

40 Pep1(h) has at least 8 contiguous amino acids contained in the following sequence:

5 Cys⁵²-Ser-Trp-Lys-Gly-Ser-Gly-Leu-Thr-His-Glu-Ala-His-Arg-Lys-Glu-Val-
Glu-Gln-Val-Tyr-Leu-Arg-Cys,

and preferably is the following sequence:

Arg-Lys-Glu-Val-Glu.

10 Pep2(h) has at least 8 contiguous amino acids contained in the following
sequence:

Cys²⁰¹-Thr-Ser-Asp-Phe-Ala-Val-Arg-Gly-Ser-Ile-Gln-Gln-Val-Thr-His-Glu-
Pro-Glu-Arg-Gln-Asp-Ser-Ala-Ile-His-Leu-Arg-Val-Ser-Arg,

and preferably is the following sequence:

Glu-Pro-Glu-Arg-Gln-Asp.

15 Pep3(h) has at least 8 contiguous amino acids contained in the following
sequence:

Gly²⁸³-Cys-Ala-Pro-Arg-Phe-Lys-Asp-Phe-Gln-Arg-Met-Tyr-Arg-Asp-Ala-
Gln-Glu-Arg-Gly-Leu-Asn-Pro-Cys-Glu-Val-Gly-Thr-Asp ,

and preferably is the following sequence:

20 Arg-Asp-Ala-Gln-Glu-Arg.

An advantageous polypeptide of the invention is characterized by the fact that
it is constituted by the sequence represented on Figure 3, extending from the
extremity constituted by amino acid at position (1) to the extremity constituted by
amino acid at position (311) or that it contains at least one of the following
25 peptides:

- * Cys-Ser-Trp-Lys-Gly-Ser-Gly-Leu-Thr
- * Val-Glu-Trp-Met-Tyr-Pro-Thr-Gly-Ala-Leu-Ile-Val-Asn-Leu-Arg-Pro-
Asn-Thr-Phe-Ser-Pro-Ala
- * Asp-Ser-Ser-Gly-Ala-Asn-Ile-Tyr-Leu-Glu-Lys-Thr-Gly-Glu-Leu-Arg-
30 Leu-Leu-Val
- * Leu-Glu-Gln-Gly-Gly-Leu-Phe-Val-Glu-Ala-Thr-Pro-Gln-Gln-Asp-Ile
- * Arg-Arg-Thr-Thr-Gly-Phe-Gln-Tyr-Glu-Leu
- * Leu-Ser-Ala-Pro-Cys-Arg-Pro-Cys-Ser-Asp-Thr-Glu-Val-Leu-Leu-Ala
- * Arg-Gln-Lys-Ser-Arg-Val-Phe
- * Cys-Gly-Val-Arg-Pro-Gly-His- Gly
- 35 * Phe-Leu-Phe-Thr-Gly-His
- * Leu-Gly-Cys-Ala-Pro-Arg-Phe
- * Asp-Phe-Gln-Arg-Met-Tyr-Arg

40 An advantageous polypeptide of the invention is constituted by the sequence
represented on Figure 2, extending from the extremity constituted by amino acid at
position (1) to the extremity constituted by amino acid at position (311).

5 The invention also relates to the muteins deriving from anyone of the above-defined polypeptides and containing modifications consisting of substitution, and/or deletion and/or addition of one or several amino acids, insofar that said modifications do not alter the hydropathicity profile as defined in Kyte and Doolittle (1982) and such as is represented in Figure 6a and 6b.

10 The above-mentioned substitution is carried out by replacing one or more amino acids by their synonymous amino acids. Synonymous amino acids within a group are defined as amino acids which have sufficient physicochemical properties to allow substitution between members of a group in order to preserve the biological function of the molecule. Synonymous amino acids are those preferably
15 listed in Table I.

	Amino acids	Synonymous groups
20	Ser	Ser, Thr, Gly, Asn
	Arg	Arg, His, Lys, Glu, Gln
	Leu	Leu, Ile, Met, Phe, Val, Tyr
	Pro	Pro, Ala, Thr, Gly
	Thr	Thr, Pro, Ser, Ala, Gly, His, Gln
25	Ala	Ala, Pro, Gly, Thr
	Val	Val, Met, Ile, Tyr, Phe, Leu, Val
	Gly	Gly, Ala, Thr, Pro, Ser
	Ile	Ile, Met, Leu, Phe, Val, Ile, Tyr
	Phe	Phe, Met, Tyr, Ile, Leu, Trp, Val
30	Tyr	Tyr, Phe, Trp, Met, Ile, Val, Leu
	Cys	Cys, Ser, Thr
	His	His, Gln, Arg, Lys, Glu, Thr
	Gln	Gln, Glu, His, Lys, Asn, Thr, Arg
	Asn	Asn, Asp, Ser, Gln
35	Lys	Lys, Arg, Glu, Gln, His
	Asp	Asp, Asn, Glu
	Glu	Glu, Gln, Asp, Lys, Asn, His, Arg
	Met	Met, Ile, Leu, Phe, Val

5 As to deletions or insertions of amino acids, they may also be introduced into the defined sequences provided they do not alter the biological functions of said sequences. Preferentially such insertions or deletions should be limited to a few amino acids and should not remove or physically disturb or displace amino acids which are critical to the functional conformation.

10 Muteins of the proteins of the invention are proteins having a sequence homologous to the sequence disclosed in the invention in which amino acid substitutions, deletions, or insertions are present at one or more amino acid positions. Said muteins may have a biological activity which is at least 10% of the polypeptides of the invention and which can be higher than the biological activity
15 of the invention, and thus do not necessarily have to be identical to the biological function of the proteins of the disclosure.

In another embodiment of the invention, muteins derived from the protein sequences of the invention or polypeptides derived from said proteins may be used to block the biological function of the proteins of the invention. Preferably, such
20 an embodiment is composed of polypeptides minimally containing about 7 amino acids and maximally having about 100 amino acids.

Another preferred embodiment contains polypeptides or muteins of the protein of the invention which comprise more than about 100 amino acids of a sequence contained in any one of the polypeptide sequences of the invention.

25 The proteins of the invention have interesting biological functions.

The term biological function means that the proteins, the muteins, and the polypeptides either provoke the proliferation of the target cell line, as can be measured by different methods such as the incorporation of ^3H -thymidine, direct cell counting or 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT)-staining (Mossman, 1983), or provoke alterations in the differentiation state
30 of the target cell line as can be measured by the changes in cell membrane marker distribution or the modulation of the biological activity of the target cell, or provoke mobilization or chemotaxis of the target cell line as can be measured by counting the cells migrating through microporous membranes.

35 According to another embodiment of the invention, the above-defined peptides have at least one of the following properties:

- promoting the incorporation of ^3H -thymidine in rat femur preosteoblast and osteoblast cells, in 3-week-old mice thymocytes, in splenic cells or lymph node cells advantageously upon costimulation with IFN- γ ,
- 40 - promoting the incorporation of ^3H -thymidine in thymocytes, advantageously upon costimulation with IL-4,
- promoting the activation, cytotoxicity or mobility of LAK cells,

- 5 - promoting the recruitment of suppressive peritoneal exudate cells upon injection in vivo,
- promoting the generation of immunocompetent lymph node cells, preferentially after ConA, PHA or LPS induction, upon in vivo intrafootpath injection,
- 10 - exerting a trypanocidal or trypanolytical activity on the pleomorph bloodstream trypanosomes in vitro.

Promoting the incorporation of ^3H -thymidine in rat femur osteoblast cells corresponds to an increased proliferation of the cells and can be carried out according to the technique as described in the examples.

- 15 Promoting the incorporation of ^3H -thymidine in 3-week-old thymocytes, advantageously upon costimulation with IL-4, corresponds to an enhanced cell proliferation and can be carried out as described in the examples.

 Promoting the incorporation of ^3H -thymidine in splenic cells or lymph node cells, advantageously upon costimulation with IFN- γ , corresponds to an enhanced cell proliferation and can be carried out as described in the examples. Promoting the mobility of LAK cells can be carried out as described in the examples. Promoting the recruitment of suppressive peritoneal exudate cells, promoting the generation of immunocompetent lymph node cells, and exerting a trypanocidal activity can be measured as described in the examples.

- 25 As to the activity or cytotoxicity of LAK cells, the activity of the polypeptides of the invention can be shown by the use of anti-sense primers derived from the nucleotides of the invention which are capable of reducing or blocking the activation or cytotoxicity of LAK cells, or the IL-2-generated expression of the polypeptides of the invention.

- 30 It should be clear that the addition of IL-2 in order to promote the activation or the cytotoxicity of LAK cells is accompanied by the induction of the mRNA of the polypeptides of the invention.

 The protein of the invention induces the uptake of ^3H -thymidine upon its addition to thymocytes in the presence of a lectin (PHA or ConA or others), with such uptake being enhanced by coincubation with cytokines (IL-4, IL-2, IL-1, IL-6 or combinations of these). In another preferred embodiment, the composition of the invention induces the uptake of ^3H -thymidine when added to splenic cells and lymph node cell populations in the presence of a lectin, with such uptake being enhanced by coincubation with IFN- γ . In another preferred embodiment, the composition of the invention induces the differentiation of splenic cells into LAK cells when added together with IL-2.

35

40

5 It is to be noted that the above-mentioned polypeptides are derived from the
expression products from the nucleotide sequence coding for a protein of 30 or
34 kDa present in the culture fluids of human and mouse macrophages,
respectively, in the human monocytic cell lines U-937 (ATCC 1593), and in the
10 cell line Mono Mac 6 (Ziegler-Heitbrock) or in the mouse cell line PU5-1.8.
(ATCC TIB61).

The invention also relates to the purified natural mammalian proteins, muteins
thereof, and polypeptides derived from them. "Purified" corresponds to the
proteins obtained according to the process as specified in the examples.

15 The invention also relates to the amino acid sequences constituted by the
above-mentioned polypeptides and a protein or a heterologous sequence with
respect to said polypeptide, with said protein or heterologous sequence comprising,
for instance, anywhere from about 10 to about 100 amino acids.

The invention also relates to the nucleic acid sequences containing or
constituted by:

- 20 - a nucleotide sequence which is effectively homologous with the nucleotide
sequences coding for the above-defined polypeptides,
- a nucleotide sequence liable to hybridize with anyone of the nucleotide
sequence coding for the above-defined polypeptides,
- or a nucleotide sequence which, further to translation or further to
25 transcription and to translation, leads to anyone of the above-defined polypeptides,
- or the complementary sequences of the above-mentioned nucleotide
sequences.

An "effectively homologous" nucleotide sequence derived from the sequence
of the invention is at least fifty percent homologous to the sequence to be isolated.
30 More preferably, the effectively homologous nucleotide sequence is at least
seventy-five percent homologous to the sequence to be isolated. Most preferably,
the effectively homologous nucleotide sequence is at least ninety percent
homologous to the sequence to be isolated. Homology, as used herein, is a measure
of similarity between nucleotides or amino acids and can be expressed as the
35 fraction of nucleotides or amino acids in the nucleotide sequence that are identical
to the sequence to be isolated.

An advantageous nucleic acid of the invention comprises or is constituted by:

- a nucleotide sequence which is effectively homologous with the nucleotide
sequence of Figure 1,
40 - a nucleotide sequence liable to hybridize with the complementary strand of
the nucleotide sequence of Figure 1,
- the nucleotide sequence of Figure 1,

- 5 - the complementary sequences of the above-mentioned sequences ,
 - the above-mentioned sequences wherein T is replaced by U.

Another advantageous nucleic acid of the invention comprises or is constituted by:

- 10 - a nucleotide sequence which is effectively homologous with the nucleotide
 sequence of Figure 2,
 - a nucleotide sequence liable to hybridize with the complementary strand of
 the nucleotide sequence of Figure 2,
 - the nucleotide sequence of Figure 2,
 - the complementary sequences of the above-mentioned sequences,
 - the above-mentioned sequences wherein T is replaced by U.

Another advantageous nucleic acid of the invention comprises or is constituted by:

- 20 - a nucleotide sequence which is effectively homologous with the nucleotide
 sequence of Figure 3,
 - a nucleotide sequence liable to hybridize with the complementary strand of
 the nucleotide sequences of Figure 3,
 - the nucleotide sequence of Figure 3,
 - the complementary sequences of the above-mentioned sequences,
 - the above-mentioned sequences wherein T is replaced by U.

25 Appropriate hybridization conditions between human cDNA and mouse cDNA
 are the following ones:

- 30 - hybridization temperature: 42°C,
 - hybridization medium: 47% deionized formamide, 10% dextrane sulfate, 3 x
 SSPE (3.6 M NaCl, 0.2 M NaH₂PO₄, 0.02 M EDTA, pH 7.4), 1% SDS, 0.5%
 milk powder,
 - wash temperature: 50°C
 - wash medium: 1 x SSC, 0.1% SDS.

35 The invention also relates to a recombinant nucleic acid containing at least one
 of the above-mentioned nucleic acids combined with or inserted in a heterologous
 nucleic acid.

The invention also relates to a recombinant vector particularly for cloning
 and/or expression, comprising a vector sequence, notably of the type plasmid,
 cosmid, phage, or virus DNA and a recombinant nucleic acid as mentioned above,
 inserted in one of the nonessential sites for its replication.

40 The invention also relates to a recombinant vector as defined above and
 containing necessary elements to promote the expression in a cellular host of
 polypeptides coded by nucleic acids of the invention, inserted in said vector and

5 notably a promoter recognized by the RNA polymerase of the cellular host, particularly an inducible promoter, and possibly a sequence coding for transcription, termination and possibly a signal sequence and/or an anchoring sequence.

10 The invention also relates to a recombinant vector as defined above, containing the elements enabling the expression of a nucleotide sequence coding for the polypeptide of the invention as a mature protein or as part of a fusion protein; the fusion moiety which is used in the fusion protein is a part of a nonhomologous protein (such as mTNF) chosen to optimize the expression of the fusion protein.

The sequence of mTNF in pmTNF is described in Figure 8a and 8b.

15 The invention also relates to a cellular host chosen from among bacteria such as *E. coli* or chosen from among eukaryotic organisms, such as COS1 cells, which is transformed by a recombinant vector defined above and containing the regulatory elements enabling the expression of the nucleotide sequence coding for the polypeptide of the invention in this host.

20 The invention also relates to viral vectors such as vaccinia virus or baculovirus, in which a recombinant nucleic acid is inserted in a nonessential site for virus replication, with said viral vectors being capable of infecting various eukaryotic cells or cell lines, resulting in the production of biologically active recombinant polypeptides of invention.

25 The invention also relates to an expression product of a nucleic acid expressed by a transformed cellular host as defined above.

The invention also relates to antibodies themselves formed against the polypeptides according to the invention.

30 It goes without saying that this production is not limited to polyclonal antibodies.

It also relates to any monoclonal antibody produced by any hybridoma liable to be formed according to classical methods from animal splenic cells, particularly from a mouse or rat, the cells of the animal being immunized against the purified polypeptide of the invention on the one hand, and of cells from a myeloma cell line on the other, and to be selected by the ability of the cell line to produce the monoclonal antibodies recognizing the polypeptide which has been initially used for the immunization of the animals.

The invention also relates to any antibody of the invention labeled by an appropriate label of the enzymatic, fluorescent, or radioactive type.

40 The peptides which are advantageously used to produce antibodies, particularly monoclonal antibodies, are the following:

These probes can be from 15 to the maximum number of nucleotides of the selected nucleic acids. The oligonucleotides can also be used either as amplification primers in the PCR technique (Mullis and Faloona, 1987) to generate specific enzymatically amplified fragments and/or as probes to detect fragments amplified between bracketing oligonucleotide primers.

35 The amplification process or the detection process or both can be specific. The latter case, giving the higher specificity, is preferred. Examples of primers are the following:

40

1)sense primer: 5'-AGGGAGGCTTATTTGTGGAGG-3'

antisense primer: 5'-GGATATGATAGAGCGACTGAGC-3'

5 denaturation T: 95°C
annealing T: 56°C
elongation T: 72°C

366 386
| |
10 2)sense primer : 5'-CCGAGAGGCACGCAGCAAGGA-3'
753 732
| |
antisense primer : 5'-CCGACAGGGGGCAGACAGCACG-3'
denaturation T: 95°C
15 annealing T: 60°C
elongation T: 72°C

For man:
20 98 118
| |
1)sense primer: 5'-GCTGCTCCTGCTCCTGGCCGG-3'
546 526
| |
25 antisense primer: 5'-GGTCCGACGCCCTGTGCCTC-3'
denaturation T: 95°C
annealing T: 64°C
elongation T: 72°C

30 247 265
| |
2)sense primer: 5'-AGTGGATGTACCCAACAGG-3'
398 378
| |
35 antisense primer: 5'-TACCAGCAGTCTCAGTTCTCC-3'
denaturation T: 95°C
annealing T: 50°C
elongation T: 72°C

40 The invention also relates to a process for preparing a polypeptide according to the invention comprising the following steps:

- the culture in an appropriate medium of a cellular host which has previously been transformed by an appropriate vector containing a nucleic acid according to the invention,

- 5 - the recovery of the polypeptide produced by the above-said transformed cellular host from the above-said culture, and
 - the purification of the polypeptide produced.

In case of a fusion protein in which the fusion moiety is, for instance, part of mTNF, purification can be achieved by immunoaffinity chromatography.

- 10 If the fusion protein contains in addition to the fusion moiety a stretch of at least 2 histidines, purification can be achieved by immobilized metal affinity chromatography (IMAC) as detailed in the examples.

- 15 In a particular case, the fusion protein is composed of a polypeptide which, in the host (eukaryotic or prokaryotic) used for the expression of the protein, acts as a natural signal sequence for the expression of the polypeptides of the invention in the culture medium. In a particular embodiment, this signal sequence can be the naturally occurring signal sequence as present in the cDNA sequences of the invention. Purification can be achieved by applying a Mg^{++} /dextrane sulphate precipitation followed by sequential liquid chromatography steps, including
20 hydrophobic interaction chromatography such as phenyl sepharose fast flow chromatography (Pharmacia), ion exchange chromatography such as Mono-Q Sepharose (Pharmacia), glycoprotein binding matrices such as Phenylboronate agarose (Amicon) and gelfiltration such as Superdex 75 (Pharmacia) or TSK100 (Merck).

- 25 Purification of the natural protein or muteins thereof can be achieved by using sequential liquid chromatography steps as detailed above.

The polypeptides of the invention can be prepared according to the classical techniques in the field of peptide synthesis.

The synthesis can be carried out in homogeneous solution or in solid phase.

- 30 For instance, the synthesis technique in homogeneous solution which can be used is the one described by Houbenweyl (1974).

The polypeptides of the invention can also be prepared in solid phase according to the methods described by Atherton and Sheppard (1989).

- 35 The invention also relates to a process for preparing the nucleic acids according to the invention.

A suitable method for chemically preparing the single-stranded nucleic acids (containing at most 100 nucleotides of the invention) comprises the following steps:

- DNA synthesis using the automatic β -cyanoethyl phosphoramidite method described in Bioorganic Chemistry 4; 274-325 (1986).

- 40 In the case of single-stranded DNA, the material which is obtained at the end of the DNA synthesis can be used as such.

5 A suitable method for chemically preparing the double-stranded nucleic acids (containing at most 100 bp of the invention) comprises the following steps:

- DNA synthesis of one sense oligonucleotide using the automatic β -cyanoethyl phosphoramidite method described in Bioorganic Chemistry 4; 274-325 (1986), and DNA synthesis of one antisense oligonucleotide using either the above-mentioned automatic β -cyanoethyl phosphoramidite method, or enzymatic transcription of the sense-strand using a specific primer hybridizing to the 3'-end of the sense strand,

- combining the sense and antisense oligonucleotide by hybridization in order to form a DNA duplex,

15 - cloning the DNA duplex obtained into a suitable plasmid vector and recovery of the DNA according to classical methods such as restriction enzyme digestion and agarose electrophoresis, or by PCR amplification according to the procedure outlined above.

A method for the chemical preparation of nucleic acids with lengths greater than 100 nucleotides - or base pairs, in the case of double-stranded nucleic acids - comprises the following steps:

- assembling the synthesized oligonucleotides, provided at their ends with different restriction sites, the sequences of which are compatible with the succession of amino acids in the natural peptide, according to the principle described Urdea et al., (1983),

- cloning the DNA thereby obtained into a suitable plasmid vector and recovery of the desired nucleic acid according to classical methods such as restriction enzyme digestion and agarose gel electrophoresis.

30 The purified natural mammalian proteins are preferentially extracted from the culture fluid of human and mouse macrophages and from the culture fluid from human monocytic cells and cell lines such as U937 (ATCC 1593) and Mono Mac 6 (Ziegler-Heitbrock) and from mouse monocytic cell lines such as PU5-1.8. (ATCC TIB61).

35 As derived from said culture fluids, the human protein has a mobility on SDS-polyacrylamide gels corresponding to a molecular weight of 30 kDa under reduced conditions and of 27 kDa under nonreduced conditions; the mouse protein has a molecular weight of 34 kDa under reduced conditions and of 30 kDa under nonreduced conditions, and may be present as proteins carrying post-translational secondary modification such as glycosylation, phosphorylation (but not limited to these).

40

5 The invention also relates to the process of purification of the natural proteins, the recombinant proteins, the muteins thereof and polypeptides derived from them as specified in the examples.

Said compositions can be used for the treatment of mammalian cells in vitro as shown in the examples.

10 The mRNA derived from the cDNAs of the invention can be found in several mammalian cell lines including, but not limited to:

PU5-1.8 (ATCC TIB61), L-929 (ATCC CCL1), NIH 3T3 (ATCC CRL 1658), U-937 (ATCC 1593), Mono Mac 6 (Ziegler-Heitbrock, see above) or CTLL (ATCC TIB 214).

15 The said mRNA can also be found in mammalian cell lines after application of external stimuli including, but not limited to: lipopolysaccharide (LPS), phorbol 12-myristate 13-acetate diester ($C_{36}H_{56}O_8$)(PMA), retinoic acid ($C_{20}H_{28}O_2$)(RA) and IL-2. Preferentially, said mRNA can be detected by Northern blotting (Fourney et al., 1988) or by the polymerase chain reaction (Saiki et al., 1985) in
20 Mono Mac 6 cells either stimulated or nonstimulated by LPS and in mouse natural killer (NK) cells derived from mouse spleen after treatment with IL-2 as specified in the examples.

The invention also relates to an antibody characterized as being specifically directed against a polypeptide according to the invention.

25 The invention also relates to polypeptides containing epitopes which can be used to raise monoclonal or polyclonal antibodies. Said polypeptides are composed of a string of amino acids having a sequence homologous to or synonymous with the disclosed sequence. Preferentially, said epitopes contain minimally 8 amino acids. A preferred embodiment of the invention contains the sequence (hu clone 5
30 peptide I, peptide II, or peptide III). It should be understood that said epitope-containing polypeptides can be used to generate antibodies capable of interfering with the blocking of the biological function of the proteins, the muteins thereof, and the polypeptides derived from them. The polypeptides may be used themselves or in combination with the antibodies in the diagnosis of the polypeptides or the
35 antibodies. Either or both may be labelled or unlabelled for use in diagnostic assays. A large number of such assays are described in the literature and include the binding, either directly or indirectly, of these polypeptides or antibodies to a variety of labels including, but not limited to, enzymes, radionucleides, fluorescers, chemiluminescers, coenzymes, particles, or the like. The antibodies to
40 these polypeptides (AB1) may be used themselves as antigens to produce anti-idiotypes (AB2) which may serve as competitive antigens having epitopic sites competitive with the epitopic sites of these polypeptides. These anti-idiotypes AB2

5 may therefore be used as substitutes for the polypeptides or as antagonists to these polypeptides. These AB2 anti-idiotypes may themselves be used as antigens to produce anti-anti-idiotypes (AB3) to these polypeptides which may serve as substitutes for AB1, having complementarity-determining regions competitive with the complementarity-determining regions of AB1.

10 The invention also relates to the use of the proteins of the invention, muteins thereof or peptides derived from them for the selection of recombinant antibodies by the process of repertoire cloning (Perrson et al., 1991).

The invention relates to nucleotidic probes, hybridizing with any of the above-defined nucleic acid sequences.

15 Preferred oligonucleotide probes of the cDNAs of the invention are the following:

Human probes:

probe 1: 5'-TTCACGGACTCCTCGGGGGCCAATA-3'

probe 2: 5'-TGGCCTGGAGCAGGGCGGCCTGTTC-3'

20 probe 3: 5'-ACAGGCTTCCAGTACGAGCTGGTTA-3'

Mouse probes:

probe 1: 5'-GGGCTCACCCGAGAGGCACGCAGCA-3'

probe 2: 5'-ATCAAGCCTTTCAGGGACTCCTCTG-3'

probe 3: 5'-AACAGGCTTCACAGGCAGAAGAGCA-3'

25

By way of example and not intended to be limiting, a typical protocol for the hybridization of these nucleotidic probes with any of the above-defined nucleic sequences bound to a solid support (e.g. a nitrocellulose membrane) is described below.

30 The membranes were prehybridized in a mixture containing the following components: 3 x SSC (1 x SSC is 0.15 M NaCl plus 0.015 M sodium citrate, pH 7.0), 25 mM sodium phosphate buffer (pH 7.1), 20% (v/v) deionized formamide, 0.02% Ficoll (type 400, Sigma), 0.02% bovine serum albumin, 0.02% polyvinylpyrrolidone, 0.1 mg sheared heat-denatured salmon sperm DNA ml⁻¹,
 35 and 0.2% SDS, usually for 0.5 - 1 h at the appropriate temperature. The hybridization mixture had the same composition except that approximately 10⁶ c.p.m. of ³²P-labelled probe ml⁻¹ was added. Hybridizations were performed at the same temperature for 1-2 h. The membranes were washed for 30 min in 3 x SSC, 25 mM sodium phosphate buffer (pH 7.1), 20% (v/v) deionized formamide,
 40 0.2% SDS at the hybridization temperature.

The optimal hybridization and wash temperatures are:

human probe 1: 57°C

5 human probe 2: 62°C

human probe 3: 54°C

mouse probe 1: 62°C

mouse probe 2: 54°C

10 mouse probe 3: 54°C.

The invention relates to a process for detecting the capacity of a molecule to behave as a ligand or as a receptor with respect to a polypeptide of the invention, characterized by:

- contacting the molecule with a cellular host which has previously been transformed by a vector itself modified by an insert coding for said polypeptide, this host carrying on its surface one or several specific sites of this polypeptide, possibly after induction of the expression of this insert, with said contacting being carried out under conditions enabling a binding to occur between at least one of these specific sites and said molecule if it happens to present an affinity for said polypeptide,

- detecting the possible formation of a complex of the type ligand-polypeptide or receptor-polypeptide.

The invention also relates to immunogenic compositions containing, as active substance, at least one of the polypeptides of Figure 2, or anyone of the peptides pep1(h), pep2(h), or pep3(h).

The invention also relates to pharmaceutical compositions containing, as active substance, at least one of the polypeptides of the invention or of the antagonists of the polypeptides of the invention as antitumor compounds, as anti-inflammatory compounds, as growth activators of T-cells or B-cells, as bone repair compounds as inducer of immunosuppressive cells, as inhibitors of anti-colony stimulating factor, or as trypanocidal agents; or part of the polypeptides of the invention, capable of binding to the above-defined receptor.

Said compositions can be used for the treatment of mammalian cells in vitro as detailed in the examples.

More particularly, the polypeptides of the invention and the AB1, AB2 and AB3 antibodies will find utility in various ways either as diagnostic reagents or as therapeutic agents, especially in the field of tumor therapy, macrophage activation and deactivation, T-cell ontogenicity, osteoblast proliferation and proliferation inhibition, LAK cell mobilization, generation and cytotoxicity, T- and B-cell growth and anti-colony stimulating activity, immuno-suppressive activity and trypanocidal activity.

5 The invention also relates to the process in which the proteins of the invention, their muteins, or polypeptides derived from them are used for the isolation and characterization of cellular receptors or binding molecules which are capable of forming a complex with said compound. As stated herein, a receptor is characterized by its localization on the cell membrane, its ability to bind to the compounds of the invention, and its ability to produce signal transduction upon binding, thereby leading to an altered state of the cell on which said receptor is present. Binding molecules as referred to herein are those molecules which are capable of interacting with the compounds of the invention in such a way that this interaction is stable under physiological circumstances. Preferentially such molecules are capable of forming said complexes between temperatures of 0°C and 45°C, between pH 2 or 11 or at ionic strengths not higher than those of a 2 M NaCl solution.

15 In case AB1 antibodies are capable of neutralizing the biological functions of the composition of the invention, the AB3 antibodies may contain the internal image of the naturally occurring receptors for the composition of the invention. AB3 antibodies may therefore be used in diagnostic assays for the measurement of receptor amounts and as antagonist to these receptors. For the same reason AB2 antibodies can be used as an agonist of these receptors.

20 The invention also relates to antisense oligonucleotides or antisense mRNA derived from the nucleotide sequences of the invention.

25 Such antisense oligonucleotides may be introduced into cells and cell lines expressing the nucleotide sequence of the invention by methods known to those skilled in the art. Antisense mRNA of which the sequence can be deduced from the sequences of the invention can also be expressed in cells and cell lines by methods known to those skilled in the art. In doing so, these antisense oligonucleotides or antisense mRNA may interfere with the translation of the sequence of the invention thereby effectively blocking the biological role of these expressed mRNAs. Preferably these anti-sense oligonucleotides can be introduced into cells or cell lines according to methods known by the man skilled in the art such as those found in Wickstrom et al. (1988).

30 Said antisense oligonucleotides contain preferentially a sequence of 8 or more nucleotides having sequences effectively homologous to the sequence of the disclosure. In a preferred embodiment, an antisense oligonucleotide of the sequence (5'-CACCGCACCCCGCAT-3' reverse complement of the 5' to 3' mouse sequence from position 187 to 201) is used.

35 These antisense oligonucleotides can also be introduced into cells or cell lines by transfection of a plasmid in which the gene encoding the protein is in the

5 opposite orientation with respect to the promoter (Izant and Weintraub (1984, 1985).

The invention also relates to nonhuman mammalian transgenic animals which contain, in their genomes, a nucleic acid sequence of the invention, and which can be used to study the effects of pharmacological compositions and to prepare
10 different cell types from these transgenic animals which express the gene of the invention in a constitutive or inducible way.

More particularly, a transgenic nonhuman animal can be prepared according to the protocol described by Gordon (1989).

Transgenic animals can be prepared by transformation of suitably adapted
15 polynucleotide sequences derived from the invention in embryonic stem cells. In a preferred embodiment, the embryonic stem cells belong to the mouse embryonic stem cell line ES (Wagner et al., 1985).

Said sequences can also be introduced by direct injection into fertilized oocytes. The methods for adaptation of said nucleotide sequences to make them
20 capable of transformation or for injection are known by those skilled in the art (Gordon, 1989).

A variant transgenic animal is a "knock-out" animal prepared according to Capecchi (1989).

More particularly, "knock-out" nonhuman mammalian transgenic animals are
25 such that the natural gene (effectively homogenous with the nucleotide sequences of the invention) is rendered nonfunctional, for instance by homologous recombination, with said animal being suitable for the study of the possible loss of functions or the possible restoration effects caused by the reintroduction into the animals of the polypeptides of the invention.

30

Description of the figures

Figure 1 represents the human genomic sequence of the cDNA of the invention.

Its characteristics are the following:

SEQUENCE TYPE: nucleotide with corresponding protein

35 SEQUENCE LENGTH: 3741 base pairs

STRANDNESS: single

TOPOLOGY: linear

ORIGINAL SOURCE: human

IMMEDIATE EXPERIMENTAL SOURCE: spleen tissue from healthy adult

40 FEATURES: from 1980 to 2188 bp intron 1 (only partially sequenced: estimated length \pm 5400 bp)

- 20
- 5 from 2575 to 2766 bp intron 2 (only partially sequenced: estimated length \pm 7900 bp)
from 2827 to 2875 bp intron 3 (only partially sequenced: estimated length \pm 1000 bp)
S: G or C
10 M: A or C
R: A or C
K: T or G
Y: T or C
(X): either present or absent.

15

Figure 2 represents the nucleotide sequence of the human cDNA homologous to the mouse cDNA sequence of the invention.

Its characteristics are the following:

- 20 SEQUENCE TYPE: nucleotide sequence with corresponding protein
SEQUENCE LENGTH: 1487 base pairs
STRANDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: copy DNA
25 ORIGINAL SOURCE
ORGANISM: human
IMMEDIATE EXPERIMENTAL SOURCE
NAME OF THE CELL LINE: THP-1
FEATURES:
30 from 1 to 5 bp: 5' non-coding region
from 6 to 140 bp: signal sequence as predicted by Von Hejine G. Nucl. Acids Res. (1986) 14:4683.
from 141 to 938 bp: mature peptide
from 939 to 1487 bp: 3' non-coding region.

35

Figure 3 represents the nucleotide sequence of the mouse cDNA of the invention.

Its characteristics are the following:

- SEQUENCE TYPE: nucleotide with corresponding protein
SEQUENCE LENGTH: 1362
40 STRANDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: copy DNA
ORIGINAL SOURCE

5 ORGANISM: mouse

IMMEDIATE EXPERIMENTAL SOURCE

NAME OF CELL LINE: PU5-1.8.

FEATURES:

from 1 to 186 bp: 5' non-coding region

10 from 187 to 321 bp: signal sequence as predicted by Von Heijne G. NAR (1986) 14:4683.

from 322 to 1119 bp: mature peptide

from 1120 to 1362 bp: 3' non-coding region.

15 Figure 4 represents the sucrose gradient fractionation of LPS-induced PU5-1.8. cells. mRNA of PU5-1.8. cells which is prepared using the Nonidet-P40 lysis method followed by a poly-A⁺ purification over oligo-dT as described in section 1.2. 400 μ g of poly-A⁺-RNA were further fractionated on a 5-20% sucrose gradient prepared in 10 mM Tris-HCl, pH 7.5, 1 mM EDTA. Gradients were run
20 in a SW40 rotor for 19 hours at 40,000 rpm in a Beckman ultracentrifuge at 4° C. After centrifugation, 0.4 ml fractions were collected and each fraction was assayed for the presence of mTNF mRNA by injection of 50 nl of each fraction in 15 oocytes of Xenopus laevis in 200 μ l of incubation medium. After 24 hours, the oocyte incubation medium was assayed for the presence of biologically active
25 mTNF by incubating 100 μ l with 4-5 x 10⁴ L-929 cells in the presence of 1 μ g/ml of actinomycin D essentially as described by Ruff and Gifford (1983). The fractions 16, 17 and 18, containing the maximal TNF activity and containing the 17S mRNA population were pooled and used for the preparation of the 17S LPS-induced PU5-1.8. cDNA library.
30 The x-axis corresponds to the numbers of fractions, the left y-axis corresponds to the optical density of 260 nm and the right y-axis corresponds to the TNF toxicity.

Figure 5 represents the alignment of the human and mouse amino acid sequence encoded by the open reading frame from nucleotide position 6 to 938 on the human
35 and position 187 to 1061 on the mouse cDNA sequence presented in Fig. 2 and 3, respectively. Both sequences share 77.4% homology. The ten CYS residues conserved between human and mouse are boxed as well as the computer-predicted antigenic peptides. The synthetic oligopeptides used to raise antibodies are underlined.

40 Figure 6a and Figure 6b represent the respective hydropathicity profile of the human and mouse amino acid sequences of the invention as depicted in Fig. 2 and 3.

Figure 7 represents the Northern blot analysis of mRNA of different uninduced and LPS-induced cell lines to determine the degree of macrophage specificity and LPS inducibility of the selected LPS-induced cDNA clone of mouse PU5-1.8 cells.

Poly-A⁺ RNA of the different cell lines here analyzed was prepared using the Nonidet-P40 lysis method followed by purification by column chromatography over oligo-dT essentially as described by Fransen et al. (1985). mRNA was separated on a denaturing formaldehyde gel as described by Gerard and Miller (1986) (2.5 µg poly-A⁺ RNA per lane) and blotted on a nylon membrane (Hybond-N, Amersham) as described by Fourney et al. (1988). The blot was screened by hybridization with the 900 bp EcoRI-restriction fragment of the selected mouse cDNA clone labelled to specific activity of 0.5-1 x 10⁹ cpms/µg using a multiprime labeling kit (Amersham, RPN 1600Y). Prehybridization was for 2 hours at 42° C in 5 x Denhardts (100 x Denhardts: 20 g Ficoll, 20 g polyvinylpyrrolidone and 20 g BSA (fraction V) per liter), 5 x SSC (20 x SSC: 3 M NaCl, 0.3 M Na acetate.2H₂O), 50 mM Na Phosphate pH 7.0, 0.1% SDS, 250 µg/ml salmon sperm DNA and 50% deionized formamide. Hybridization was performed for at least two nights in the same buffer containing 1 x 10⁶ cpms/ml of the labelled probe. Thereafter, the filter was washed two times in 2 x SSC, 0.1% SDS followed by two washes in 1 x SSC, 0.1% SDS, each time for 15 minutes and at 50° C. Autoradiographical exposure was for two hours at room temperature.

Messenger RNA of the following cell lines are analyzed: mouse monocytic PU5-1.8. either uninduced (3 h and 24 h: lanes 1 and 3) or LPS-induced (3 h and 24 h: lanes 2 and 4); 24 hours uninduced and LPS-induced mouse macrophage 2C11-12 cells (lanes 5 and 6); 24 hours uninduced and LPS-induced mouse T-lymphoma EL-4 (lanes 7 and 8); 24 hours uninduced and LPS-induced mouse B-myeloma NSo (lanes 9 and 10); and 24 hours uninduced and LPS-induced mouse fibrosarcoma L-29 (lanes 11 and 12). LPS-induction was as described in section 1.1.

Figure 8a is a schematic representation of the bacterial expression plasmid pmTNF-MPH.

Figure 8b represents the total DNA sequence of the bacterial expression plasmid pmTNF-MPH.

5 Figure 9 represents the SDS-PAGE gel analysis of *E. coli* strain transformed with the expression plasmid pmTNF-MPH-PU1280-Eco47III at different times after temperature-induced expression.

Lanes 1 to 5: pmTNF-MPH-PU1280-Eco47III in K12ΔH after 1 h, 2 h, 3 h, 4 h and 5 h induction at 42°C; lane 6: pmTNF-MPH-PU1280-Eco47III in K12ΔH after
10 5 h induction at 28°C; lanes 7-8: pmTNF-MPH in K12ΔH after 5 h induction at 28°C and 42°C, respectively.

A culture of K12ΔH harbouring pmTNF-MPH-PU1280-Eco47III, grown overnight in Luria broth at 28°C with rigorous shaking in the presence of 10 µg/ml tetracycline, was inoculated into fresh Luria broth containing tetracycline
15 (10 µg/ml) and grown to an optical density at 600 nm of 0.2 under the same conditions as for the overnight culture. At this density of bacterial growth, half of the culture was shifted to 42°C to induce expression, while the other half remained at 28°C as a control. At several time intervals, aliquots were taken which were extracted with one volume of phenol equilibrated against M9 salts (0.1% ammonium chloride, 0.3% potassium dihydrogen phosphate, 1.5% disodium
20 hydrogen phosphate, 12 molecules of water) and 1% SDS. At the same time the optical density at 600 nm of the culture is measured. The proteins are precipitated from the phenol phase by addition of two volumes of acetone and stored overnight at -20°C. The precipitate is pelleted (Biofuge A, 5 min, 13000 rpm, room temperature), air dried, dissolved in a volume of Laemmli sample buffer (+ β-mercaptoethanol) according to the optical density of the culture sample and
25 boiled for 3 minutes. Samples were then put on a SDS polyacrylamide gel (12.5%) according to Laemmli (1970). Afterwards the gel was first treated for at least 1 hour at 4°C with a 10% trichloroacetic acid solution and subsequently immersed in a 1/10 diluted CBB-staining solution (0.5 g CBB-R250 (Serva) in 90 ml of methanol: H₂O (1:1 v/v) and 10 ml glacial acetic acid) and left for about one hour on a gently rotating platform. After destaining in 30% methanol - 7% glacial acetic acid (two to three washes of about 30 min each) the gel was dried between two sheets of cellophane at room temperature.

35

Figure 10 is a schematic representation of the expression vector pSVL used for transient expression of the mouse and human polypeptide of the invention in COS1 cells. Apart from prokaryotic sequences (ORI of replication and AMP resistance
40 gene), the vector contains the SV40 origin of replication (SVORI) and part of the SV40 late region: SV40 late promoter and enhancer (SV40L) sequence, the 5' untranslated region (5UTR) followed by a multilinker sequence, donor and

- 5 acceptor splice sites of the late 16s mRNA (INTRON) and the late SV40 polyadenylation site (poly A).

10 Figure 11 is a 2-dimensional nonequilibrium pH gel electrophoresis (2D-NEPHGE) (non-reducing conditions) and fluorography of 5 ml conditioned medium of COS1 cells transfected with the expression plasmid pSV-PU1280-HdIII (A) or the control plasmid pSV (B) radiolabeled with ^{35}S -methionine (24 h) as described. The ± 30 kDa triple peptide spot corresponding to the mouse polypeptide of the invention is indicated by an arrow.

15 Figure 12 represents the separation on an aquapore butyl 7 μ column (Brownlee - 10 cm x 2.1 mm) of peptides generated by partial formic acid hydrolysis (as described) of the mouse polypeptide of the invention as secreted by pSV-PU1280-HdIII-transfected COS1 cells. Peptides were eluted with a linearly increasing gradient of 0.1% trifluoroacid (TFA) in acetonitrile and detected by UV
20 absorbance at 214 nm. Peptides 20/24/26 and 27 were selected for sequencing (Applied Biosystems 477 A).

25 Figure 13 represents the 2-dimensional non-equilibrium pH gel electrophoresis (2D-NEPHGE) (non-reducing conditions) and fluorography of 5 ml CM of COS1 cells transfected with the expression plasmid pSV-T1200 containing the human analogue of the invention cDNA (A) or the control plasmid pSV (B), radiolabeled with ^{35}S -methionine as described (24 h). The ± 27 -kDa peptide spot corresponding to the human polypeptide of the invention is indicated by an arrow.

30 Figure 14 represents the SDS-polyacrylamide gel electrophoresis (non-reducing conditions) and fluorography of proteins secreted in 1 ml conditioned medium (CM) of Sf9 cells ($\pm 10^6$ cells) infected with either wild type baculovirus (lane 1) or recombinant baculovirus containing the mouse cDNA of the invention (lanes 2, 3, 4, 5) and radiolabeled with ^{35}S -methionine for 18 h, 24 h post-infection as
35 described.

The ± 28 kDa protein corresponding to the mouse polypeptide of the invention is indicated by an arrow.

40 Figure 15 represents the 2D-NEPHGE (reducing conditions) analysis and fluorography of 5ml CM of HeLa cells infected with recombinant vaccinia virus containing the mouse cDNA of the invention (A) or wild type vaccinia virus (B),

- 5 labeled with ^{35}S -methionine for 24 h post- infection. The \pm 34 kDa protein of the invention is indicated by an arrow.

10 Figure 16 is a Western blot analysis with the anti-human peptide 3 polyclonal antiserum, of 5 ml CM of HeLa cells infected with recombinant vaccinia virus containing the human cDNA of the invention (24 h harvest)(A) or wild type vaccinia virus separated on 2D-NEPHGE (reducing conditions). The \pm 30 kDa protein of the invention is indicated by an arrow.

15 Figure 17 is the Western blot analysis with the anti-mTNF-MPH-mouse cDNA fusion protein antiserum of proteins secreted in 20 ml CM of LPS-induced (10 $\mu\text{g/ml}$; 24 h) PU5-1.8 cells, separated on 2D-NEPHGE (reduced conditions). The mouse polypeptide of the invention is indicated by an arrow. TNF which is also recognized by the antiserum is also indicated.

20 Figure 18 represents the immunoprecipitation of the native form of the mouse polypeptide of the invention secreted by transfected COS1 cells, with the anti-mTNF-MPH-mouse cDNA fusion protein antiserum.

25 850 μl of ^{35}S -methionine-labeled CM of COS1 cells transfected with pSV control plasmid (lane 1) or pSV-PU1280-HdIII plasmid (lane 2) was immunoprecipitated as described and analyzed by SDS-PAGE-fluorography (lanes 3 and 4 correspond to pSV and pSV-PU1280-HdIII, respectively). The immunoprecipitated mouse polypeptide of the invention is indicated by an arrow.

30 Figure 19 represents the characterization of the N-glycosylation of the mouse polypeptide of the invention by N-glycosidase F treatment:

35 500 μl CM of uninduced (A) or LPS (24 h, 10 $\mu\text{g/ml}$) induced PU5-1.8 cells (B), of wild type vaccinia virus infected (C) or recombinant mouse cDNA vaccinia virus infected HeLa cells (D), of recombinant mouse cDNA baculovirus-infected Sf9 cells (E) or pSV-PU1280-HdIII transfected COS1 cells (F) was untreated (-) or treated with N-glycosidase F (+) (as indicated by the manufacturer) and analyzed by Western blotting with the anti-mTNF-MPH-mouse cDNA fusion protein antiserum.

40 Figure 20 represents the thymocyte proliferation assay as described in section 12.1. performed in the presence of 2 $\mu\text{g/ml}$ of PHA and a two-fold serial dilution of the mouse polypeptide of the invention (rec prot: start concentration \pm 5-10 ng/ml) or pSVL control medium. The proliferation was measured by the incorporation of

- 5 ^3H -thymidine for 24 hours following a 72-hour incubation of the cells with the samples (see y-axis representing the amount of CPM x 1000). As negative control, conditioned medium of pSVL-transfected COS1 cells, treated in exactly the same way as the medium obtained from pSV-PU1280-HdIII-transfected cells or PBS, was tested in the presence of PHA.
- 10 For each group of three contiguous rectangles, the left rectangle corresponds to the recombinant protein of the invention, the middle rectangle corresponds to the negative control (pSVL) and the right rectangle corresponds to the control. The x-axis corresponds to the two-fold serial dilutions wherein the number 1 represents the start concentration of 5 to 10 ng/ml of the polypeptide of the invention, 2 represents 2 times less, etc.
- 15

- Figure 21a and Figure 21b represent the proliferative effect of the mouse polypeptide of the invention respectively on rat pre-osteoblast cells (Fig. 21a) and osteoblast cells (Fig. 21b). The assay was performed as described in section 12.5.
- 20 both on preosteoblast and osteoblast cells by adding a two-fold serial dilution of the mouse polypeptide of the invention (rec prot: start concentration \pm 5 ng/ml) or pSVL (see Fig. 20) as negative control. 5% of fetal calf serum (FCS) and 1% of bovine serum albumin (BSA) were included as positive and negative assay controls, respectively.
- 25 The y-axis represents the amount of CPM x 1000 and the x-axis corresponds to serial dilutions. For each group of two contiguous histograms, the left one corresponds to the recombinant protein of the invention, while the right one corresponds to pSVL; the highest single histogram corresponds to FCS (5%) while the lowest single one corresponds to BSA.
- 30

- Figure 22 represents the trypanocidal effect of the polypeptide of the invention on Trypanosma brucei brucei in vitro. The assay was performed as described in section 12.6 on 2×10^6 parasites by adding a two-fold serial dilution of the mouse polypeptide of the invention (recombinant protein start concentration: 50 ng/ml) or PBS (negative control). The y-axis represents the % of trypanocidal activity of living parasites and the x-axis corresponds to serial dilutions.
- 35

EXAMPLES

- 40 1. Preparation of libraries

5 1.1. Lipopolysaccharide (LPS)-induction of the mouse macrophage cell line
PU5-1.8

The established mouse monocyte/macrophage cell line PU5-1.8 (PU.5-1R)
(purchased from the American Type Culture Collection, Baltimore, MD, USA;
10 ATCC TIB61) was chosen for lipopolysaccharide, endotoxin (LPS)-induction.
However, other mouse cell lines of the monocyte-macrophage lineage (such as
J-774, RAW309, WR19M, Wehi3B, etc.) or primary macrophages (peritoneal
macrophages, alveolar macrophages) can also be used. Cells of the PU5-1.8 cell
line were cultured as spinner cultures in RPMI-1640 medium enriched with 10%
15 non-inactivated preselected batches of fetal calf serum (FCS, Gibco, Paisley,
Scotland). When reaching a density of 1 to 1.5×10^6 cells/ml, cells were
subcultured at a starting density of 5×10^5 cells/ml in roller bottles in the same
growth medium. At confluence ($\pm 1.5 \times 10^6$ cells/ml), the cells were washed 3
times with RPMI-1640, resuspended at a cell concentration of 3.5×10^6 cells/ml in
20 RPMI-1640, and stimulated by addition of 10-15 $\mu\text{g/ml}$ of LPS (LPS *E. coli*
055:B5 Difco Laboratories, Detroit, MI, USA) for 20-24 hours. After induction
the cells were collected by centrifugation, washed three times with icecold
phosphate-buffered saline (PBS) and stored at -70°C until preparation of the
mRNA. Also, mRNA was prepared from uninduced PU5-1.8 cells. To this end,
25 cells were treated as indicated for LPS-induced cells but without addition of LPS
during induction. The conditioned medium of untreated and LPS-induced PU5-1.8
cells was tested for the presence of $\text{TNF-}\alpha$, IL-1 and IL-6 using appropriate
bioassays. TNF activity was assayed on L-929 cells (Ruff and Gifford, 1980). IL-1
activity was measured using an indirect assay system (Van Damme et al. 1987).
30 IL-6 was measured in terms of hybridoma growth activity (Van Snick et al., 1986)

1.2. Preparation of LPS-minus and LPS-plus mRNA of PU5-1.8 cells

As a source of mRNA, uninduced (LPS-minus) and LPS-induced (LPS-plus)
PU5-1.8 cells were used. Total cytoplasmic RNA was extracted by lysing the cells
35 in Nonidet P-40 followed by phenol extraction of the lysate as described (Fransen
et al., 1985). Polyadenylated RNA (poly A^+ -RNA) was purified from total RNA
by oligo dT- cellulose chromatography (Type 3; Collaborative Research, Boston,
MA, USA) as described by Chirgwin et al. (1979). The resulting RNA was further
fractionated on a 5-20% sucrose gradient in 10 mM Tris-HCl, pH 7.5, 1 mM
40 EDTA by centrifugation at 40,000 rpm for 19 hours at 4°C .

5 1.3. Construction of a cDNA library of a 17S-mRNA fraction of LPS-induced
 PUS-1.8 cells

10 The mRNAs from the 17S fraction of the gradient (the fraction numbers 16,
 17, 18 of the gradient as shown in Fig. 4) of LPS-induced mRNA of PU5-1.8 cells
 15 were used for the construction of the cDNA library. These fractions were selected
 on the basis of their capacity to induce the synthesis of mTNF upon injection in
Xenopus laevis oocytes. The conditions used for the construction of a cDNA
 library in pAT153 plasmids were chosen according to established state-of-the-art
 methods. To this end, the RNA from the 17S fraction was precipitated by addition
 of 0.1 volume of 2 M Na acetate pH 5.3 and 2 volumes of ethanol; the precipitate
 was redissolved in water and the solution was heated for two minutes at 70°C and
 then quickly chilled on ice. The conditions for the first-strand synthesis were as
 follows:

- 20 - \pm 50 μ g poly A⁺ RNA/ml
- 50 mM Tris HCl, pH 8.3
- 50 mM KCl
- 10 mM MgCl₂
- 10 mM DTT
- 0.5 mM of each dNTP (N = A, T, C, or G) with 1/1000 dCTP replaced
 25 by α (³²P)-dCTP at 800 Ci/mmol (code PB 10385, Amersham,
 Buckinghamshire, England)
- 60 μ g/ml poly dT₁₀ (Pharmacia, Uppsala, Sweden)
- 1000 U/ml human placental RNase inhibitor (Amersham,
 Buckinghamshire, England)
- 30 - 1000 U/ml reverse transcriptase (Biores, Waerden, The Netherlands)

 The reaction was performed in a total volume of 100 μ l at 41°C for 1 hour.
 The reaction mixture was then extracted once with
 phenol/chloroform/isoamylalcohol (25/24/1), twice with diethyl ether, and the
 DNA was precipitated by adding 1 volume of 4 M ammonium acetate and 4
 35 volumes of ethanol. The pellet was redissolved in water and the precipitation step
 was repeated.

 The precipitate was redissolved in 60 μ l 15 mM potassium phosphate buffer,
 pH 6.9, 0.25 mM EDTA and treated with 2 μ g RNase A (Boehringer Mannheim,
 FRG) at 37°C for 30 minutes. Subsequently, the mixture was boiled for 2 minutes
 40 and immediately quenched on ice. Potassium phosphate buffer, pH 6.9, MgCl₂,
 DTT and dNTPs were added to final concentrations of 100 mM, 10mM, 10 mM,
 and 1 mM, respectively. The reaction was initiated by addition of 330 U/ml E. coli

5 polymerase I (Boehringer Mannheim). Second-strand synthesis was performed at 15°C for 6 hours in a total volume of 300 μ l. The reaction was stopped by adding EDTA, pH 8.0 to a final concentration of 25 mM and the mixture was phenol-extracted and precipitated as described (see above). The precipitate was redissolved in 125 mM NaCl, 25 mM sodium acetate, 1 mM zinc acetate, pH 4.5 and treated
 10 with 20 units of S1-nuclease (BRL, Neu-Isenburg, FRG) for 20 minutes at 37°C. The reaction was stopped by the addition of EDTA pH 8.0 to a final concentration of 20 mM, neutralized by the addition of Tris-HCl, pH 8.0 to a final concentration of 200 mM and again phenol-extracted as mentioned above. Finally, the dsDNA was precipitated by addition of 1/10 volume potassium acetate, pH 4.8 and 1
 15 volume of isopropanol.

The pellet was redissolved in buffer containing 30 mM NaCl, 10 mM Tris-HCl, 1 mM EDTA, pH 8.0 and size-fractionated on a Biogel A 50m gel filtration column (0.8 x 12 cm) (Biorad, CA, USA) equilibrated against the same buffer. Fractions containing DNA of >500 base pairs were pooled and precipitated as
 20 above.

The double-stranded cDNA was oligo(dC) tailed using the following conditions:

- \pm 2 μ g double-stranded cDNA/ml
- 100 mM potassium cacodylate, pH 7.2
- 25 - 2 mM CoCl_2
- 200 μ M DTT
- 40 μ M deoxy (5- ^3H)cytidine triphosphate (17 Ci/mmol; Amersham)
- 400 Units/ml terminal deoxynucleotidyl transferase (Pharmacia)

The reaction was performed at 37°C until around 20-25 dC residues were
 30 incorporated per 3' OH-end and was stopped by the addition of EDTA pH 8.0 to a final concentration of 25 mM followed by phenol extraction, ether extraction, and precipitation as described above.

Oligo dG-tailing of the PstI-digested plasmid pAT153 was carried out under similar conditions except that 4 μ M deoxy (8- ^3H) guanosine 5' triphosphate (25
 35 Ci/mmol; Amersham) was used instead of 40 μ M d(^3H) cytidine 5' triphosphate, and that the concentration of the linearized plasmid DNA was 16 pmole/ml. The oligo dC-tailed double-stranded cDNA was annealed with the oligo dG-tailed vector as described (Maniatis et al., 1982.).

The *E. coli* strain DH1(λ) was transformed (Hanahan, 1983) using 10 ng of
 40 vector DNA per 100 μ l of competent cells. Transformation mixtures were plated on Millipore HATF (0.45 μ m) filters (Millipore, Bedford, MA, USA) and layered on top of Luria broth (LB) agar plates containing 10 μ g/ml of tetracycline. After

- 5 propagation, the filters were placed on fresh LB-agar plates also containing 20% glycerol and stored at -20°C. In this way, a 17S mouse cDNA library of about 25,000 clones was obtained.

2. Isolation of the cDNA clones coding for the selected sequence

2.1. Isolation of the selected mouse cDNA

2.1.1. Plus-minus screening of the 17S mouse PU5-1.8 cDNA library

15 The colonies were lysed in situ and fixed on replicas of the mouse cDNA library (Hanahan and Meselson, 1980). Two sets of replicas were screened by differential hybridization: the plus probe being a ^{32}P -labelled cDNA from LPS-induced PU5-1.8 17S mRNA, the minus probe being ^{32}P -labelled cDNA from uninduced PU5-1.8 17S mRNA. This cDNA was synthesized essentially as
20 previously described (see 1.3.) except that only 15 μM of dCTP was used, to which $\alpha(^{32}\text{P})$ dCTP (6000 Ci/mmol, Amersham) was added to a concentration of 2 μM . Colony hybridization was carried out at 42°C for 40 h in 20% deionised formamide, 5 x SSC, 5 x Denhardt solution, 25 mM sodium phosphate buffer pH 6.5, 20 $\mu\text{g}/\text{ml}$ of sonicated and denaturated *E. coli* DNA and ^{32}P -labelled cDNA
25 probe (10^6 cpm/ml) after an overnight prehybridization in the same buffer but without labelled cDNA.

Before autoradiography, the filters were washed three times for 30 minutes in 2 x SSC, 0.1% SDS at 42°C.

30 The clones that showed preferential hybridization with the plus probe were picked up, grown individually, and streaked on new filters for a second round of plus/minus hybridization. Those clones that were consistently positive in both rounds of hybridization were retained. They are referred to as "LPS-induced" clones.

35 2.1.2. Characterization of a selected LPS-induced cDNA fragment from the PU5-1.8 cDNA library

40 Of all the LPS-induced mouse clones isolated by plus-minus screening, DNA was prepared using the Triton X100-lysozyme lysis method essentially as described (Kahn et al., 1979). The length of the cDNA insert was assessed by digestion with the restriction enzyme *Pst*I and by separating the insert from the pAT153 vector by agarose gel electrophoresis.

5 The selected LPS-induced clone has an insert of 446 bp, divided into two subfragments of 332 bp and 114 bp by an internal PstI site.

This clone was characterized with respect to its degree of LPS inducibility, its macrophage cell-type specificity, and its gene expression in other cells of the immune system (T cells and B cells) by Northern blot analysis. The selected LPS-
 10 induced gene fragment hybridized only with a mRNA of an approximate length of 1475 base pairs present in uninduced or LPS-induced mouse macrophage cells and not with mRNA of uninduced or LPS-induced EL-4, and NSo cells, and very weakly with mRNA of uninduced or LPS-induced L929 cells. Hence, the selected gene fragment behaved as LPS-induced and as being dominantly expressed in
 15 macrophage.

2.1.3. Construction of a LPS-induced PU5-1.8 cDNA library in λ ZAP II

In order to obtain the full-size cDNA information of the selected LPS-induced
 20 PU5-1.8 cDNA fragment, a cDNA library was constructed in the λ ZAP II vector system (Stratagene, La Jolla, CA, USA). To this end, mRNA was prepared from PU5-1.8 cells induced for 3 hours with LPS (see section 1.1.). The synthesis of cDNA was performed as described (section 1.3.) except that it was not tailed with dGTP or dCTP but rather was methylated by dissolving the cDNA pellet in a
 25 solution of 100 mM Tris-HCl, 10 mM EDTA, pH 8.0, 80 μ M S adenosyl-methionine (Sigma, St. Louis, MO, USA) and 1.5 U/ml of RI methylase (Promega, Madison, WI, USA) for 60 minutes at 37°C. The enzyme was inactivated by heat treatment (10 minutes at 70°C) and, after cooling to room temperature, MgCl₂, DTT, dXTPs and T4 DNA polymerase (Boehringer
 30 Mannheim, FRG) were added up to a final concentration of 7 mM, 5 mM, 0.2 mM and 125 units/ml, respectively. The reaction was performed at 18°C for 1.5 hours. The enzyme was heat-inactivated and the reaction mixture was phenol-extracted and precipitated as above.

Phosphorylated EcoRI linkers (Pharmacia, Uppsala, Sweden) were ligated to
 35 the blunt-ended dsDNA at 13°C for 48 hours at a ratio of 40:1 for the 3 hours LPS-induced PU5-1.8 cDNA libraries constructed in λ ZAP II in a ligation buffer containing 1 mM ATP, 50 mM Tris-HCl pH 7.4, 10 mM DTT, 8 mM MgCl₂ and, 0.5 U/ml T4 ligase (Boehringer-Mannheim, FRG). The mixture was subsequently heat-treated (10 minutes at 70°C) and, after cooling to room temperature, Tris-
 40 HCl, pH 7.4, NaCl, MgCl₂, DTT, and EcoRI enzyme were added to final concentrations of 50 mM, 100 mM, 10 mM, 10 mM, and 3000 U/ml, respectively. Digestion was performed for at least 2 hours at 37°C. The material was then

5 phenol-extracted, ethanol-precipitated, and fractionated by gel filtration over
 Biogel A 50-m (Biorad, Richmond California, USA). All DNA fragments larger
 than ± 400 bp were pooled, freeze dried, and redissolved in 50 mM Tris-HCl, pH
 7.4, 12 mM MgCl₂, 12 mM MgCl₂, 10 mM ATP, 1 mM DTT. To this end, a
 10 solution of T4-ligase (Boehringer-Mannheim, FRG) was added to a concentration
 of 0.5 U/ μ l and ligation was performed for at least 3 hours at 16°C at a molar ratio
 of 1:2 of insert versus vector for the 3-hour LPS-induced PU5-1.8 cDNA libraries
 constructed in λ ZAP II. Packaging of the ligation mixture into phage particles was
 performed using a packaging mix from Promega (Madison, WI, USA) according to
 the protocol recommended by the supplier, except that the chloroform treatment
 15 was omitted. The cDNA library constructed in the λ ZAP II cloning vector was
 amplified on XL-1 blue cells (Stratagene) and contained 1.8×10^6 independent
 plaques.

2.1.4. Screening for the full-size mouse cDNA corresponding to the LPS- 20 induced gene fragment from the PU5-1.8. cDNA library

The corresponding full-size mouse sequence was picked up by screening the
 LPS-induced PU5-1.8. λ ZAP II cDNA library (section 2.1.3.). Therefore, the
 library was plated out and plaque-lifted in duplo, using 5- and 8-minute adsorption
 25 times, respectively, on Hybond-N membranes (Amersham). The DNA was
 denatured by alkaline treatment (0.2 N NaOH, 1.5 M NaCl) neutralized in a Tris
 HCl buffer (1 M Tris-HCl, pH 7.5; 1.5 M NaCl) followed by a final wash in 2 x
 SSC and fixed on the membranes by incubation for 2 hours at 80°C under vacuum.
 The filters were screened by hybridization using both *Pst*I cDNA fragments of the
 30 selected LPS-induced mouse clone cDNA fragment as radioactive probe. The
 cDNA fragment was labelled to high specific activity ($\pm 8 \times 10^8$ cpm/ μ g) with
 α (³²P)dCTP (3000 Ci/mmol; 10 mCi/ml; Amersham) using a multiprime DNA
 labelling procedure as provided by Amersham. The filters were prehybridized for
 20-24 hours at 50°C in a solution containing 50% deionized formamide,
 35 4 x SSPE, 1% SDS, 0.5% milk powder and 500 μ g/ml denaturated salmon sperm
 DNA. Hybridization was allowed to proceed for at least 48 hours at 50°C in 47%
 deionized formamide, 10% dextrane sulfate, 3 x SSPE, 1% SDS, 0.5% milk
 powder using 0.5 - 1×10^6 cpm/ml of probe/ml.

A first wash was performed in 2 x SSC, 0.1% SDS at 30°C followed by
 40 different washes in 1 x SSC, 0.1% SDS at 50°C or at a higher temperature until
 the background was acceptable. After autoradiography, plaques showing positive
 hybridization on both filters were further plaque-purified.

5 Purified plaques were excised in vivo and recircularized by infecting with f1-helper phage to generate the pBluescript phagemids as described by the supplier (Stratagene, La Jolla, CA, USA). Using these phagemids, DNA was prepared, the cDNA inserts were characterized by partial restriction mapping, and inserts were sequenced.

10 The combined data allow depiction of the mouse nucleotide sequence coding for the protein corresponding to the selected LPS-induced gene (Fig. 3).

The sequence, numbered from nucleotide 1 to 1362, contains an ATG initiation signal at nucleotide position 187, opening a reading frame of 933 bp that codes for a protein of 311 amino acids (TGA stop codon on nucleotide position 15 1120). The 3'-end sequence is 243 nucleotides long and contains the 3'-TTATTAT (position 1329), resembling the cytokine consensus sequence 3'-TTATTTAT (Caput et al., 1986), and a short poly A stretch of 11 A residus. However, this part of the cDNA will most propably not be complete as no AATTAAA polyadenylation signal is present at the end of the sequence. The derived amino 20 acid sequence encodes a protein with a calculated molecular weight of 34.5 kDa that contains a computer-predicted N-terminal signal peptide of around 40 amino acids with a hydrophobic core of Pro and Leu residues, preceeded by a rather basic N-terminal region. Algorithms to detect membrane-spanning or membrane-associated amino acid sequences show negative results. Furthermore, the sequence 25 contains a putative N-glycosylation signal (Asn-Leu-Thr; amino acid position 103) and 10 Cys residues.

2.2. Isolation of the cDNA clone encoding the human homologue of the selected mouse polypeptide of the invention

30

2.2.1. Induction of the human THP-1 cell line for the selected gene product

The human monocytic THP-1 cell line (ATCC TIB202) was chosen for the screening of a human cDNA library to pick up the human sequence corresponding to the mouse sequence of the selected LPS-induced gene. However, other human 35 pre-monocytic cell lines (e.g. J111 or HL60), macrophage cell lines (U937 or Mono Mac6), or human macrophage cells isolated from placenta or alveolar fluid can be used although it should be understood that for each of these human cells or cell lines a specific induction scheme for the optimal production of the product may be required. For the production of our polypeptide, the THP-1 cells were seeded at 40 2×10^5 cells/ml in roller bottles in RPMI-1640 enriched with 10% fetal calf serum. Three days later, at a cell density of 8×10^5 cells/ml, the cells were centrifuged and concentrated to a cell density of 10^6 cells/ml in RPMI-1640 - 10%

5 FCS enriched with 400 IU/ml of human recombinant interferon-gamma (h-rIFN- γ).
 Twenty-four hours later, the cells were washed twice with serum-free medium and
 induced for 6 hours at a cell density of 10^6 cells/ml in serum free-medium with 10-
 15 μ g/ml of LPS. Thereafter, the cells were collected by centrifugation, washed
 10 twice with icecold PBS and stored as a dry cell pellet at -70°C until preparation of
 the mRNA.

2.2.2. Preparation of THP-1 mRNA and construction of a human LPS- induced, h-rIFN- γ -activated THP-1 cDNA library and screening of the library for the full-size human sequence homologous to the selected mouse cDNA fragment

15

The in vitro induced THP-1 cells prepared as described above were used as a
 source of human monocytic mRNA. The polyadenylated RNA was extracted from
 the cells as described in section 1.2. for the PU5-1.8. cells. After quality control
 by sucrose gradient centrifugation, this mRNA was used for the construction of a
 20 human macrophage cDNA library in the λ ZAP II phagemid.

The human THP-1 cDNA library was constructed essentially as described in
 section 2.1.3. for the PU5-1.8. λ ZAPII cDNA library. Starting from 0.5 μ g THP-
 1 mRNA, a human macrophage cDNA library was constructed in λ ZAPII of $1.5 \times$
 10^6 independent plaques. After amplification, the library had a titer of 10^9 pfu/ml
 25 and was stored at -70°C in the presence of 7% DMSO.

Next, 5×10^5 pfu of the LPS-induced h-IFN- γ -activated THP-1 cDNA
 λ ZAP II library was screened using the ^{32}P -labelled 990 bp *Eco*RI restriction
 fragment of the previously isolated selected mouse cDNA as radioactive probe.
 The cDNA was labelled to high specific activity ($\pm 8 \times 10^8$ cpm/ μ g) with
 30 α -(^{32}P)dCTP (300 Ci/mmol; 10 mCi/ml; Amersham) using a multiprime DNA
 labelling procedure as provided by Amersham. The plaque lifts were prepared as
 described for the screening of the mouse cDNA libraries (see section 2.1.4.). The
 filters were prehybridized for 20-24 hours at 42°C in a solution containing 50%
 deionized formamide, 4 x SSPE, 1% SDS, 0.5% milk powder and 0.5 mg/ml
 35 denaturated salmon sperm DNA. Hybridization was allowed to occur for at least
 48 hours at 42°C in 47% deionised formamide, 10% dextran sulfate, 3 x SSPE,
 1% SDS, 0.5% milk powder using $0.5 - 1 \times 10^6$ cpms of radiolabelled probe/ml.
 After hybridization, a first wash was performed in 2 X SSC, 0.1% SDS at room
 temperature for 15 minutes followed by a second wash in 1 X SSC, 0.1% SDS for
 40 20 minutes at 50°C and a final wash in 2 X SSC, 0.1% SDS for 20 minutes at
 55°C . After autoradiography, phages showing positive hybridization on both
 plaque lifts were further plaque-purified. The longest clone we isolated contains an

5 insert of 1487 bp (Fig. 2) and predicts an open reading frame starting from the first
 ATG at position 6 to position 938, specifying a polypeptide of 311 amino acids.
 Unlike the analogously selected LPS-induced mouse clone, the human sequence
 does not contain an internal EcoRI site. The 5'-end is 5 nucleotides long and will
 most probably be incomplete. The 3'-untranslated region is 548 nucleotides long
 10 and may be complete since an AATAAA polyadenylation signal (position 1466) is
 present at the end of the sequence. The 3' end region also contains the 5'-TATTAT
 sequence resembling the cytokine consensus sequence (Caput et al., 1987),
 conserved between the selected human and mouse clone. The nucleotide sequence
 of both human and mouse share 73.8% homology (data not shown). The sequence
 15 predicted by the human clone encodes for a polypeptide with a calculated MW of
 34 kDa and shows 77.4% homology with the amino acid sequence of the selected
 mouse clone (Fig. 5). The ten Cys residues are conserved in both sequences
 indicating that they may be important in the folding of the polypeptide. The
 absence of the putative N-glycosylation signal in the human sequence in contrast to
 20 the Asn-Leu-Thr code in the mouse sequence suggests that the human cDNA
 product is not glycosylated. Furthermore, the hydrophilicity plots of the human
 and mouse clone (Fig. 6) are very similar and, in both sequences, an eukaryotic
 secretory signal sequence is predicted with the most probable cleavage site between
 amino acid position 45 and 46. For both human and mouse, a mature product of \pm
 25 30 kDa should then be found upon translocation.

3. Determination of the macrophage-specificity and LPS-inducibility of the PU5-1.8. mRNA hybridizing with the selected LPS-induced cDNA

30 To define the degree of the LPS-inducibility of the selected gene, mRNA of
 uninduced and LPS-induced PU5-1.8 cells was prepared after 3 hours or 24 hours
 of induction. The macrophage-cell type specificity of the selected LPS-induced
 mouse cDNA was assessed by preparing mRNA of uninduced cells and cells
 treated with LPS according to the protocol followed for PU5-1.8. induction. As
 35 cell lines were selected (mouse macrophage hybridoma cells; Patent Application
 Innogenetics N.V. Analytical Utilisation of Phagocyte Cell Lines. 19.09.90. EP 0
 159 653 B1.), EL-4 cells (mouse T cell lymphoma; ATCC TIB39), mouse NSo
 (non-secreting mouse B cell myeloma, Kearney et al., 1979), and L929 cells
 (mouse fibrosarcoma, ATCC CCL1).

40 To this end, the cells were grown batch-wise (10^9 cells/batch) for 40 hours in
 RPMI-1640 medium enriched with 10% fetal calf serum, washed twice with
 serum-free medium and incubated for another 3 hours (for the LPS-induction of

5 PU5-1.8 cells) or 24 hours in serum-free RPMI 1640, in the absence (-LPS) or in the presence of 10-15 $\mu\text{g/ml}$ of LPS (+LPS). Thereafter, the cells were washed twice with icecold PBS and stored at -70°C until preparation of the mRNA. mRNA was prepared using the NP-40 method as described in section 1.2.

10 All mRNA preparations were run on a denaturing formaldehyde/formamide - 1.5% agarose gel (2.5 μg poly A⁺ RNA/lane) as described by Maniatis et al., (1982.) and blotted on a Nylon membrane (Hybond-N, Amersham) in 10 x SSC by Northern blotting (Fourney et al. 1988). These blots were subsequently screened by hybridization using restriction fragments of the selected clone as radioactive probe (Fig. 7).

15 The degree of the LPS-induction of the selected gene in mouse cells was evaluated by comparison of the strength of the hybridization signals obtained with the different mRNA preparations using β -actin as internal standard. Hybridization to a mRNA of 1475 bp was detected in uninduced mouse macrophage cells, but mRNA levels were slightly increased upon in vitro treatment of the cells with LPS
20 for three hours.

4. Isolation of the human gene containing the human cDNA of the invention

Starting from high quality genomic DNA, isolated from human spleen tissue
25 (Maniatis et al., 1982), a human genomic library ($6-8 \times 10^6$ independent plaques (pfu)) was constructed in the GEM11 vector (Promega) essentially as described by the supplier. From this library which has a titer of $\pm 10^{10}$ pfu/ml after amplification, 1.2×10^6 pfus were plated on MB406 (Promega) and screened for the human gene of the invention by hybridization using the full-size human cDNA
30 insert as radioactive probe. The preparation of the filters and the pre- and hybridization conditions were as described for the homologous screening of LPS-induced PU5-1.8. λ ZAP II cDNA library for the isolation of the full-size mouse cDNA of the invention (section 2.1.4.). Ten positively hybridizing plaques were picked, plaque-purified, and grown for the preparation of the recombinant phage
35 DNA. Upon further restriction mapping and Southern blotting analysis using either the full-size insert or cDNA restriction fragments located near the 5' or 3' end of the human cDNA of the invention as radioactive probe, three genomic clones (clones a, b and c) were retained for subcloning of the different *Sac*I-fragments in the pBluescript SK(+) (Stratagene) and partially nucleotide sequencing. The 5000
40 bp *Sac*I subclone of the genomic clone b contains the 5' exon fragment of the human cDNA sequence of the invention, including the ATG initiation site and extends this information until position 175 of the human cDNA where it transits in

5 the first intron sequence by the use of a classical splice donor acceptor site. The
 1500 bp *SacI*-subclone, present in all three isolated genomic clones, contains the
 second exon of the human gene of the invention from position 176 to position 561
 of the human cDNA. Finally, the 3500 bp *SacI*-subclone contains the third and
 10 fourth exon of the gene, respectively ranging from position 562 to 621 and from
 position 622 to the end of the human cDNA including the 3'-end-located AATAAA
 polyadenylation site.

5. Expression of the mouse polypeptide of the invention in *E. coli* cells

15 The DNA sequence coding for a polypeptide, or part of it, can be linked to a
 ribosome binding site which is part of the expression vector, or can be fused to the
 information of another protein or peptide already present in the expression vector.
 In the former case, the information is expressed as such and hence devoid of any
 foreign sequences (except possibly for the amino terminal methionine which is not
 20 always removed by *E. coli*). In the latter case the expressed protein is a hybrid or a
 fusion protein.

Various methods and materials for preparing recombinant vectors, either of
 plasmid, bacteriophage or cosmid nature, the procedures for transformation or
 infection in different host cells and expressing polypeptides and proteins are
 25 described by Panayatos (1981) and by Old and Primrose (1981) and are well
 known to those skilled in the art.

A suitable vector is plasmid pmTNF-MPH (Innogenetics). It contains the
 tetracycline resistance gene and the origin of replication of pAT153 (Twigg and
 Sherratt (1980) (obtainable from Biores B.V., Woerden, The Netherlands), the PL
 30 promoter up to the *MboII* site in the N gene 5' untranslated region, followed by a
 synthetic ribosome binding site (see sequence data) and the information encoding
 the first 25 amino acids of mTNF (except for the initial Leu which is converted to
 Val). This sequence is, in turn, followed by a polylinker sequence encoding six
 consecutive His residues downstream of which several proteolytic sites (formic
 35 acid, CNBr, kallikrein and *E. coli* protease VII sensitive sites) are incorporated.
 Each of these proteolytic sites is at the DNA level accessible by a unique
 restriction site. The presence of the [His]₆ sequence in the fusion peptide allows
 Ni²⁺-immobilized metal affinity chromatography (IMAC) based purification of the
 recombinant protein of interest. Downstream from the polylinker, translational stop
 40 codons are present in the three possible reading frames which in turn are followed
 by the *E. coli* trp terminator of transcription (synthetic) and the rrnBT1T2
 terminator of transcription (originating from pKK223-3; Pharmacia). The

- 5 restriction and genetic map of this plasmid is represented in Fig. 8a. The total nucleic acid sequence of this plasmid is represented in Fig. 8b.

DNA of the pmTNF-MPH-PU1280-Eco47III containing the mouse nucleotide sequence of the invention from the Eco47III restriction site at position 318 to the EcoRI cloning site (position 1364), cloned in the proper orientation into the *Sma*I site of the pmTNF-MPH, a technique well known to those skilled in the art, was transformed into *E. coli* strain K12A H (ATCC 33767) using standard transformation procedures. However, the growth temperature of the cultures is reduced to 28°C and the heat shock temperature is raised to 42°C. A culture of K12D H harbouring pmTNF-MPH-PU1280-Eco47III, grown overnight in Luria broth at 28°C with rigorous shaking in the presence of 10 µg/ml tetracycline, was inoculated into fresh Luria broth containing tetracycline (10 µg/ml) and grown to an optical density of 0.2 measured at 600 nm under the same conditions as for the overnight culture. At this density of bacterial growth, half of the culture was shifted to 42°C to induce expression while the other half remained at 28°C as a control. At several time intervals aliquots were taken which were extracted with one volume of phenol equilibrated against M9 salts (0.1% ammonium chloride, 0.3% potassium dihydrogen phosphate, 1.5% disodium hydrogen phosphate, 12 molecules of water) and 1% SDS. At the same time the optical density at 600 nm of the culture is measured. The proteins are precipitated from the phenol phase by addition of two volumes of acetone and storage overnight at -20°C. The precipitate is pelleted (Biofuge A, 5 min, 13000 rpm, room temperature), air dried, and dissolved in a volume of Laemmli (1970) sample buffer (+ β-mercaptoethanol) according to the optical density of the culture sample and boiled for 3 minutes. Samples were then run on a SDS polyacrylamide gel (12.5%) according to Laemmli (1970). Temperature induction of pmTNF-MPH-PU1280-Eco47III was monitored by both Coomassie Brilliant Blue (CBB) staining and immunoblotting.

For CBB staining, the gel was first treated for at least 1 hour at 4°C with a 10% trichloroacetic acid (TCA) solution and subsequently immersed in a 1/10 diluted CBB staining solution (0.5 g CBB-R250 (Serva) in 90 ml of methanol: H₂O (1:1 v/v) and 10 ml glacial acetic acid) and left for about one hour on a gently rotating platform. After destaining in 30% methanol - 7% glacial acetic acid (two to three washes of about 30 min each), protein bands were visualized and scanned with a densitometer (for instance Ultrosan XL Enhanced Laser sensitometer, Pharmacia LKB).

For immunoblotting the proteins were transferred onto Hybond C membranes as described by Towbin et al. (1979). After blotting, proteins on the membrane were temporarily visualized with Ponceau S (Serva) and the position of the

5 molecular weight markers was indicated. The stain was then removed by washing in H₂O.

Aspecific protein binding sites were blocked by incubating the blots in 10% non-fat dried milk for about 1 hour on a gently rotating platform. After washing twice with NT buffer (25 mM Tris Cl pH 8.0; 150 mM NaCl) blots were incubated
 10 with monoclonal anti-hTNF antibody (1/10) which cross-reacts with mTNF (Innogenetics No. 17F5D10) for at least 2 hours on a rotating platform. After washing twice with NT buffer + 0.02% Triton X100, blots were incubated for at least 1 hour with the secondary antiserum which was alkaline phosphatase-conjugated rabbit anti-mouse immunoglobulins (1/500; Sigma). Blots were washed
 15 again twice with NT buffer + 0.02% Triton-X100 and then visualized with nitro blue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) from Promega under conditions recommended by the supplier.

After induction of K12 H cells transformed with pmTNF-MPH-PU1280-Eco47III, a band of about 34 kDa appeared on CBB stained gels, which represents
 20 about 15% of total synthesis (Fig. 9). The fusion product between TNF and the selected gene product reacts clearly with anti-hTNF-monoclonal antibody (No. 17F5D10) on immunoblot.

25 6. Transient expression of the mouse and the human sequences in COS1 cells

The mouse cDNA of the invention was introduced into an expression vector comprising the SV40 origin of replication and part of the SV40 late region containing the strong SV40 late promoter and enhancer sequence followed by a multilinker sequence which is flanked by donor and acceptor splice sites of the late
 30 16S mRNA and the polyadenylation signal of the SV40 region (pSVL)(Fig.10). This type of expression vector was originally described by Gheysen et al. (1982).

The mouse cDNA sequence of the invention was introduced according to methods known to those skilled in the art into the multicloning site of this expression plasmid as a HindIII-EcoRV (multicloning site of pSP73) DNA
 35 fragment isolated from the so-called plasmid pSP73-PU1280 which contains the mouse cDNA sequence as a SphI-EcoRI fragment. Transfection of the COS1 cells (Gluzman et al., 1981)(ATCC CRL 1650) with the resulting plasmid pSV-PU1280-HdIII was done according to an optimized DEAE-transfection protocol (McCutchan and Pagano, 1968). In case of in vivo labelling of the cells with ³⁵S-
 40 methionine, the transfection of the cells was followed by two washes with methionine-free medium (DMEM or RPMI-1640) without serum, a starvation period of one hour in the same medium, and subsequent incubation in 1 ml medium

5 per 10^6 cells supplemented with ^{35}S -methionine for 24 hours ($100\ \mu\text{Ci/ml}$ ^{35}S -methionine; $1150\ \text{Ci/mM/ml}$; 10m Ci/ml).

Proteins secreted in conditioned medium of transfected cells were TCA-precipitated and analyzed on 12.5% Tricine-SDS-polyacrylamide gels (Schägger and von Jagow, 1987) or by 2-dimensional nonequilibrium pH gel electrophoresis (NEPHGE) as described by Van Fleteren et al. (1992). Production of the protein of the invention was demonstrated by either CBB staining (as recommended by the supplier, Serva), immunoblotting, or fluorography (Enhance-Dupont). For immunoblotting, proteins were electroblotted onto nitrocellulose membranes (Sartorius) and, after blocking of aspecific protein binding sites with Tween-20 (Sigma) and 3% BSA (Sigma), the membranes were incubated with polyclonal antiserum raised against the mTNF-MPH-cDNA fusion protein (1/500) (section 9.). As a second antibody, alkaline phosphatase-conjugated mouse anti-rabbit immunoglobulin (1/1000, Sigma) was used and subsequent visualization was performed with nitro blue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP)(Promega).

Transfection of COS1 cells with the pSV-PU1280-HdIII expression plasmid results in production and secretion of an extra protein with a molecular weight (MW) of approximately $\pm 30\ \text{kDa}$ (non-reduced) or $\pm 34\ \text{kDa}$ (reduced). The reduced form of the protein ($\pm 34\ \text{kDa}$) was only detectable by immunoblotting with mTNF-MPH-mcDNA antiserum, because a COS1 cell-specific protein masks the position of the 34 kDa protein. The calculated MW of the mature polypeptide coded for by the cDNA of the invention is 29.9 kDa. The higher MW of the protein produced in COS1 cells is due to glycosylation of the mouse protein as indicated by in vitro transcription-translation experiments (results not shown) and from results of the Vaccinia expression (see below).

On 2D-NEPHGE (non-reduced) the protein appears as a triple peptide spot (due to secondary modifications) with a MW of $\pm 30\ \text{kDa}$ and a pI of approximately 5.5 to 6.0 (Fig. 11).

To allow amino acid sequence confirmation of the 30 kDa protein secreted by pSV-PU1280-HdIII transfected COS1 cells, preparative amounts ($\pm 2\ \text{liters}$) of the COS1 conditioned medium were prepared and the $\pm 30\ \text{kDa}$ triple protein spot was excised from preparative Coomassie R stained non-reducing 2D-NEPHGE gels. The different spots were concentrated according to Rasmussen et al. (1991) and digested with 2% formic acid at 110°C for 4 hours (Van Fleteren et al., 1992). Peptides were separated on an aquapore butyl 7μ (Brownlee-10 cm x 2.1 mm) column and peptides AH20 and AH27 (Fig. 12) were sequenced using an Applied Biosystem 477A protein sequencer. The resulting sequences were 100%

- 5 homologous to the polypeptide sequence predicted from the mouse cDNA sequence of the invention.

In an analogous manner to the construction of the vector containing the mouse sequence, the human homologue was inserted into the vector pSVL as an EcoRI (cDNA cloning sites) DNA fragment. Transfection of COS1 cells with the
10 resulting pSV-T1200 expression plasmid results in production and secretion of a protein with a MW of ± 27 kDa (non-reduced) or ± 30 kDa (reduced). On non-reducing 2D-NEPGHE the protein appears as a protein spot with a MW of ± 27 kDa and a pI of ± 6.0 to 7.0 , without apparent indication of secondary modifications, consistent with the lack of a N-glycosylation site in the human
15 amino acid sequence (Fig. 13).

7. Expression of the selected mouse cDNA of the invention in a baculovirus expression system

20 The baculovirus expression vector system is a highly efficient eukaryotic expression vector for producing large amounts of selected polypeptides in a suitable environment for posttranslational modifications. This helper-independent recombinant virus vector has produced recombinant protein at levels ranging from 1 to 500 mg/liter (Smith et al., 1983; Smith et al., 1985).

25 The mouse cDNA of the invention was inserted into the intermediate transplacement vector pACYM1 (Matsuura et al., 1987) according to methods known to those skilled in the art.

The mouse cDNA of the invention was introduced as a BamHI fragment, derived from pSV-PU1280-HdIII, into the BamHI insertion site of the pACYM1
30 vector downstream from the strong baculoviral polyhedrin promoter. The resulting transfer vector was cotransfected with wild type baculovirus DNA (Autographa californica (mono) nuclear polyhedrosis virus AcMNPV) into Spodoptera frugiperda cells (Sf9 ATCC 1711) using a modification of the calcium phosphate precipitation technique (Graham, 1973) adapted for insect cells. Recombinant
35 virus was selected visually.

Infection of Sf9 cells with recombinant baculovirus containing the mouse cDNA of the invention results in production and secretion of an extra protein with a MW of ± 28 kDa (non-reduced) or ± 32 kDa (reduced) as determined by SDS-PAGE (fluorography and /or immunoblotting) (Fig. 14). Upon analysis of
40 condition medium on 2D-NEPGHE, the protein appears as a spot with MW ± 28 kDa (non-reduced), ± 32 kDa (reduced) and pI ± 5.5 to 6.0 . The difference in MW between the polypeptide of the invention produced and secreted by either

5 transient expression in COS1 cells or by recombinant baculovirus-infected Sf9 cells is due to differences in secondary modifications (glycosylation) of the polypeptide in the two expression systems, as could be shown by glycosylation pattern analysis using different glycosidases (results not shown).

10 8. Expression of the mouse and human cDNA of the invention in a vaccinia expression system

The vaccinia virus expression system is considered one of the more promising ways of producing significant amounts of correctly processed and modified
15 eukaryotic proteins in mammalian cells. The wide host range of the virus and its ability to infect a variety of vertebrate cell lines including macrophages makes it an especially interesting tool to express macrophage-specific proteins (Moss and Flexner, 1987).

Both the mouse and human cDNA of the invention were introduced into the
20 vaccinia genome using the intermediate transplacement vector pATA18 (Stunnenberg et al., 1988). The cDNA of the invention was introduced as a BamHI fragment, derived from pSV-PU1280-HdIII or pSV-T1200, into the BamHI insertion site of the pATA18 vector (Stunnenberg et al., 1988) downstream from the vaccinia 11 K late promoter according to methods well-known to those skilled
25 in the art. The resulting transfer vectors (pATA-PU1280-HdIII for the mouse cDNA, pATA-T1200 for the human cDNA) were transfected by the calcium phosphate method into RK13 cells (ATCC CCL 37.) defective for the TK gene (TK-) after prior infection with wild-type vaccinia virus. Recombinant progeny virions containing the cDNA of the invention were chosen using deoxyuridine
30 selection (BrDU). The technology used is well-known to those skilled in the art.

In comparison with wild-type virus infected HeLa cells (ATCC CCL 2.), infection with recombinant vaccinia virus containing the mouse cDNA of the invention results in production and secretion of an extra protein with a MW of \pm 30 kDa (non-reduced) and \pm 34 kDa (reduced) as determined by SDS-PAGE.
35 Upon analysis of the conditioned medium produced by these cells on reducing 2D-NEPHGE the protein appears as a triple peptide spot with MW of \pm 34 kDa and a pI of 5.5 to 6.0 (Fig. 15).

Infection of cells (HeLa) with recombinant vaccinia virus containing the human cDNA of the invention results in the secretion of a protein with a MW of \pm 27 kDa (non-reduced) and \pm 30 kDa (reduced). On 2D-NEPHGE, the protein
40 migrates as a peptide spot with a MW of \pm 30 kDa and a pI of 6.0 - 7.0 (Fig. 16).

5 9. Production of polyclonal antibodies against the mouse and human polypeptides of the invention

 A bacterially produced fusion protein between mTNF and the mouse polypeptide of the invention containing 6 histidine residues at the fusion position
10 (see section 5.) was prepared by starting from one liter culture of transformed bacteria (pmTNF-MPH-PU1280-Eco47III). Bacterial expression products were sulfonated prior to separation by incubating the bacterial pellet in 8 M urea, 20 mM Tris-HCl pH 7.0, 1 mM CuSO₄, 130 mM Na₂S₂O₈ and 610 mM Na₂SO₃. Twenty-four hours later the mixture was dialyzed against 7 M urea, 30 mM Tris-
15 HCl pH 7.2 and loaded on a MONO Q-Sepharose column (Pharmacia) in the same buffer. The material was eluted from the matrix using a linear salt gradient up to 1 M NaCl and resulting fractions were tested by SDS-PAGE and immunoblotting using anti-TNF antiserum. The fractions containing the fusion protein of interest (fractions 48 to 53) eluting from the column between 250 and 350 mM NaCl were
20 pooled and further purified by Ni²⁺- immobilized metal affinity chromatography (IMAC), according to the manufacturer's instructions. After elution with 100 mM imidazol the anti-TNF immunoreactive fusion protein was dialyzed against 7 M urea, 30 mM Tris-HCl pH 7.2 and subsequently used for immunization of rabbits. Technology used is well known to those skilled in the art.

25 The resulting antiserum (anti-mTNF-MPH-mcDNA) was tested for specific (cross-) reaction with the mouse and human polypeptide of the invention both by immunoblotting (detection of the denatured form of the polypeptide) and immunoprecipitation (detection of the native soluble form of the polypeptide). Several examples of the detection by immunoblotting have already been
30 demonstrated (see above). For immunoprecipitation, 850 μ l of ³⁵S-methionine-labelled conditioned medium of COS1 cells transfected with pSV, pSV-PU1280-HdIII, or pSV-T1200 was incubated with 30 μ l of antiserum. After reaction, the immunoglobulins were selectively precipitated with 30 μ l of a 50% suspension of proteinA glass beads using the procedure recommended by the supplier (Porton).
35 After binding, the supernatant was discarded and the beads were washed with PBS/0.05% Tween 20/0.01% BSA to remove the aspecific binding proteins. Subsequently, specific antibody binding proteins were eluted by boiling for 5 min in 30 μ l 1.5 x Laemmli sample buffer and analyzed by SDS-PAG-fluorography.

 By immunoblotting the anti-mTNF-MPH-mcDNA antiserum recognizes the
40 polypeptide of the invention produced in COS cells (30 kDa/34 kDa), recombinant baculovirus- infected Sf9 cells (28 kDa/32 kDa) as well as a 30 kDa/ 34 kDa protein secreted in the conditioned medium of the macrophage cell line PU5-1.8

5 (Fig. 17). The antiserum also cross-reacts with the human analogue of the polypeptide of the invention produced and secreted by COS1 cells. In addition the antiserum is also able to immunoprecipitate the native form of the mouse polypeptide of the invention as produced in COS1 cells upon transfection with pSV-PU1280-HdIII (Fig. 18).

10 Based upon computer prediction of the antigenicity of different peptides coded for by the human cDNA of the invention, a C-terminal peptide of 29 amino acids (position 283 to 311: GCAPRFKDFQRMRYDAQERGLNPCEVGTD) was chemically synthesized according to methods known to those skilled in the art (Atherton et al., 1989), coupled to hemocyanin essentially as described (Harlow, 15 1988), and injected into rabbits using classical immunization schemes. The resulting antiserum was tested in immunoprecipitation and immunoblotting experiments mainly as described earlier. It recognizes the human polypeptide of the invention secreted by pSV-T1200-transfected COS1 cells (see above) as well as the product of the human macrophage cell line Mono Mac 6 either secreted 20 constitutively or after activation. Furthermore, the antiserum was also able to immunoprecipitate the native form of the protein as it recognizes the polypeptide of the invention secreted by pSV-T1200-transfected COS1 cells.

25 10. N-glycosylation pattern of the recombinant and native mouse polypeptide of the invention

In order to study the N-glycosylation patterns of the recombinant mouse polypeptide of the invention produced in different expression systems with the native polypeptide secreted by PU5-1.8 cells, studies using the enzymatic removal 30 of glycosylic residues by N-glycosidase F (E.C. 3.2.1.96) were performed. Therefore, conditioned medium (CM) of cells secreting the mouse polypeptide of the invention or their respective negative controls were treated with N-glycosidase F under the optimal conditions as described by the manufacturer. Condition medium was then analyzed by Western blotting using the anti-mTNF-MPH- 35 mcDNA fusion protein polyclonal antiserum.

As was described, the glycosylated form of the protein of the invention has the same MW (± 34 kDa - reduced) when secreted by PU5-1.8 cells, COS1 cells, or recombinant vaccinia virus-infected cells. The recombinant baculoviral produced protein has a slightly lower MW (± 32 kDa-reduced).

40 After N-deglycosylation, both the native protein and the three eukaryotic expression systems described, shift to an apparent MW of ± 29 kDa (reduced), corresponding to the theoretical MW calculated for the mature unglycosylated

5 polypeptide of the invention (Fig. 19). These data demonstrate that the lower MW of the protein produced by insect cells results from a less complex N-glycosylation pattern of the protein. According to the literature, insect cells can carry out N-glycosylation, but the addition of high mannose to complex N-linked oligosaccharides does not appear to take place (Luckow and Summers, 1988).

10 Analogous studies were performed on the human analogue of the protein of the invention. No evidence for any N-glycosylation event was demonstrated in accordance with the lack of a N-glycosylation consensus sequence in the human protein sequence.

15 11. Purification of the mouse recombinant protein of the invention

Conditioned medium (600 ml) of COS1 cells transfected with the cDNA of the invention as described in section 6. was collected after 48 h and filtered over a 0.22 μ m filter to remove cell debris. A typical purification started from 600 to 1000 ml of COS1 transfection medium. To this mgCl_2 and dextranesulphate 500.000 (Pharmacia, Uppsala, Sweden) was added to a final concentration of 60 mM and 0.02%, respectively. After 1 h incubation at 4°C the precipitate was pelleted by centrifugation (12.000g, 30 min., 4°C). The supernatant fraction, containing the mouse polypeptide of the invention was dialysed against 50 mM Hepes pH 7.0, 4 mM EDTA, adjusted to pH8.0 and located at a flowrate of 0.5 ml/minute on a 4 ml Phenylboronate agarose (PBA 30, Amicon, MA, USA) column equilibrated in 50 mM Hepes pH 8.5. The mouse polypeptide of the invention was eluted from the matrix by 100 mM Sorbitol.

30 The Sorbitol eluted peak (\pm 25 ml) is then passed at a flowrate of 0.5ml/minute over a 1 ml FPLC Mono Q anion exchange column (Pharmacia) equilibrated in Hepes pH 8.5 and eluted with a linear salt gradient of 0 to 1 M NaCl at a flowrate of 1 ml/minute. The mouse polypeptide of the invention eluted at 125 mM NaCl in a total volume of \pm 10 ml.

35 The eluate was concentrated about 40 fold by Centricon 10.000 (Amicon) and loaded batchwise (3 times 0.25 ml) on a SMART Superdex 75 gelfiltration column (Pharmacia) equilibrated against PBS. The highly purified mouse polypeptide of the invention (>98 % pure) eluted at a molecular weight of 34 kDa, well resolved from a higher molecular weight peak containing aggregated mouse polypeptide of the invention and higher molecular weight contaminants.

purification steps	sample volume (ml)	protein conc. (μ g)
COS1 conditioned medium	600	23.000
Mg ⁺⁺ /dextranesulphate precipitate	600	N.D.
PBA Sorbitol eluate	25	750
Mono Q eluate	10 \rightarrow 0.25	45
Superdex 75 gelfiltration	3 x 0.25 or 0.75	15

12. Biological activities of the mouse recombinant protein of the invention

12.1. Proliferative effect of the mouse polypeptide of the invention on mouse thymocyte populations

Thymocytes were isolated from 3-week-old C3H mice (IFFA CREDO, France), and seeded in microtiter wells at 5×10^5 cells per well in RPMI-1640 5% FCS, 2 μ g/ml PHA, and two-fold serial dilutions of the polypeptide of the invention alone or in combination with two-fold serial dilutions of the mouse cytokines IL-1, IL-2, IL-4 or IL-6, or combinations of these (start concentration in the first well being 400 U/ml). Seventy-two hours later the cells were labelled with ³H-thymidine (1 μ Ci/well) and harvested after 24 hours for counting in a liquid scintillation counter. The mouse polypeptide of the invention when added alone elicits a thymocyte growth-proliferative effect in the presence of the lectin PHA. When tested in combination with the different cytokines, especially in the presence of IL-4, a growth-enhancing effect towards control values (counts incorporated in the presence of IL-4 alone) could be observed (Fig. 20). When testing combinations of IL-4 with other T-cell interacting cytokines (IL-1, IL-2 or IL-6) and serial dilutions and/or constant concentrations of the mouse polypeptide of the invention, a similar invention-specific growth-proliferative effect could be observed in varying degrees for the combinations of IL-4 and IL-1 or IL-2, but not with IL-6.

12.2. In vitro activity of the polypeptide of the invention on the mitogenic and allogeneic responses of lymph node and splenic cell populations

5 When properly activated, macrophages secrete monokines such as TNF- α ,
IL-1- α , IL-1- β and IL-6 that provide accessory signals for the stimulation of
peripheral T cells. Similarly, certain T-cell derived lymphokines such as IFN- γ
also play an accessory role in the activation of T cells. The mouse polypeptide of
the invention was tested for its function as an accessory signal in T-cell activation
10 either alone or in combination with other cytokines (IL-1, IL-6 or IFN- γ) always in
the presence of the lectin PHA or ConA.

When tested on ConA activation of lymph node cells (LNC) with and without
IL-1, IL-6 or IFN- γ (each time 100 U/ml), the polypeptide of the invention exhibits
an additive growth-stimulating effect and this effect is significantly increased when
15 tested in combination with IFN- γ . This effect is not observed with the accessory
molecules IL-1 and IL-6.

When the growth proliferative effect of the polypeptide of the invention was
tested on the same cell populations (LNC and SPC) but now combined with the
lectin PHA instead of with ConA, a similar growth- proliferative activity was
20 recorded upon adding the polypeptide of the invention. This effect also synergized
with IFN- γ .

T cells were depleted of accessory cells by fractionation on a nylon-wool
column, well known to those skilled in the art. The nonadherent cell fraction
represents the T-cell population while the accessory are retained by the matrix.
25 CD4+ and CD8+ T cell subpopulations are isolated from the nylon-wool non-
adherent fraction by magnetic cell sorting (MACS) separation using either anti-
CD4+ or anti-CD8+ antibodies, a technique well known to those skilled in the
art. The total LNC T-cell population, the nylon-wool nonadherent T cells, CD4+
T cells and CD8+ T cells were stimulated with ConA either as such or
30 supplemented with 5% accessory cells (mice peritoneal exudate cells). The
combined effect of the mouse polypeptide of the invention with IFN- γ was tested
on the ConA-induced proliferations of the total unfractionated lymph node cell
population or the nylon-wool nonadherent fraction or MACS purified CD4+ or
CD8+ T-cell subpopulations (Table II). On the total LNC population, a significant
35 enhancement of the proliferative response by the combined action of the mouse
polypeptide of the invention and IFN- γ could be measured, while no effect on
growth stimulation could be observed on the nylon-wool nonadherent T-cell
population, or on the MACS-purified CD4+ or CD8+ T cells. However, upon
addition of an accessory cell population (5% of peritoneal exudate cells (PEC)) to
40 the nylon wool nonadherent subpopulation, the proliferative effect of the mouse
polypeptide of the invention was partially restored. The restoration of the

- 5 enhancing effect was not observed when supplementing the purified CD4+ or CD8+ T cells with 5% PEC.

Similar experiments were performed with spleen (SPC) cell populations except that in these experiments the MACS-purified CD4+ and CD8+ T-cell populations were not included. The mouse polypeptide of the invention again demonstrated a
10 co-stimulatory effect on the T-cell growth proliferation that requires the presence of accessory cells.

On both cell populations (LNC and SPC), similar results could be recorded when using the lectin PHA instead of ConA.

The polypeptide of the invention together with IFN- γ enhances the mitogenic
15 response of T cells. This enhancing effect requires the presence of accessory cells such as macrophages.

Table II hereunder relates to the effect of the mouse polypeptide of the invention and IFN- γ on the ConA-induced proliferation of LNC populations. T cells were depleted of accessory cells by fractionation on nylon wool column
20 (nonadherent fraction represents the T-cell population), essentially as described by Julius et al. (1973). CD4+ and CD8+ T cell subpopulations were isolated by magnetic cell sorting (Miltenyl et al., 1990). T cells, CD4+ T cells and CD8+ T cells (at a cell concentration of 2×10^5 cells/ml) were stimulated for 24 hours with 2.5 μ g/ml of ConA either as such or supplemented with 5% accessory cells
25 (peritoneal exudate cells). The latter were prepared by injecting mice intraperitoneally with 5 ml of DMEM-5% glucose followed by recuperation of the injected material together with the peritoneal cell population. Twenty-four hours later the cells were pulsed with ^3H -thymidine (1 μ Ci/ml) for another 18 hours and harvested. The combined effect of the conditioned medium of the COS1-expressed
30 mouse polypeptide of the invention (rec prot) or of the CM of pSVL-transfected COS1 cells (pSVL) with 100 IU of IFN- γ was tested on the ConA-induced proliferations of unfractionated LNC populations or nylon wool nonadherent CD4+ or CD8+ subpopulations. The ratio 1/10 or 1/2 represent a one-to-ten or one-to-two dilution of the gel filtration purified material (see section 6) in the
35 bioassay test medium.

Cell population	ConA-induced proliferation		
	cpms	Δ cpms (-control)	Δ cpms (-control-IFN- γ)
<u>LNC(total)</u>	20	-	-
+IFN- γ	46	26	-
+IFN- γ + pSVL (1/10)	57	37	11
+IFN- γ + rec prot (1/10)	71	51	25
+IFN- γ + pSVL (1/2)	84	64	38
+IFN- γ + rec prot (1/2)	110	90	64
<u>LNC(nylon nonadherent)</u>	2	-	-
+IFN- γ	17	15	-
+IFN- γ + pSVL (1/10)	17	15	0
+IFN- γ + rec prot (1/10)	18	16	1
<u>LNC(nylon nonadherent) + PEC</u>	11	-	-
+IFN- γ	11	0	-
+IFN- γ + pSVL (1/10)	18	7	7
+IFN- γ + rec prot (1/10)	31	20	20
<u>LNC(CD4+)</u>	4	-	-
+IFN- γ	7	3	-
+IFN- γ + pSVL (1/10)	8	4	1
+IFN- γ + rec prot (1/10)	10	6	3

Table II (continued): Effect of the mouse polypeptide of the invention and IFN- γ on the ConA-induced proliferation of LNC subpopulations.

Cell population	ConA-induced proliferation		
	cpms	Δ cpms (-control)	Δ cpms (-control-IFN- γ)
LNC(CD4+) + PEC	27	-	-
+IFN- γ	24	0	-
+IFN- γ + pSVL (1/10)	24	0	0
+IFN- γ + rec prot (1/10)	26	0	0
LNC(CD8+)	0.3	-	-
+IFN- γ	1.2	0.9	-
+IFN- γ + pSVL (1/10)	2.2	1.9	1
+IFN- γ + rec prot (1/10)	2.6	2.3	1.4
LNC(CD8+) + PEC	16	-	-
+IFN- γ	12	0	-
+IFN- γ + pSVL (1/10)	14	0	0
+IFN- γ + rec prot (1/10)	11	0	0

10

12.3. Effect of the polypeptide of the invention on the acetyl-LDL uptake of mouse foam cells

15 J774 (ATCC TIB 76) are mouse monocytic cells that can be differentiated in vitro to mouse foam cells by treatment with acetylated low density lipoproteins (acetyl-LDL), a process that can be followed by measuring the intracellular acetyl-LDL content and the cholesterol esterification. Preincubation or co-incubation of the mouse monocytic J774 cell line with the mouse polypeptide of the invention before of during treatment with acetyl-LDL had an effect on the uptake of acetyl-LDL by the cells. Treatment of the J774 cells for 24 hours with the mouse polypeptide of the invention either before or during the treatment with acetyl-LDL increases the amount of total cholesterol in the cells. This can no longer be observed after 4 hours treatment indicating that the mouse polypeptide of the invention modulates the speed of cell uptake of acetyl-LDL. This effect could be

20

25

5 due to an up-regulation of the expression of the acetyl-LDL scavenger receptor on
the J774 cells or by another interaction of the mouse polypeptide of the invention
with acetyl-LDL or with the J774 cell membrane. Other cytokines such as IL-1,
GM-CSF and M-CSF have been described to have an effect on the cholesterol
10 metabolism of the macrophages (Ishibashi et al., 1990). For M-CSF it has been
demonstrated that the preincubation of the macrophage cells with this cytokine
enhanced the uptake and degradation of acetyl-LDL in a dose-dependent manner.
The polypeptide of the invention could act either directly on the macrophage cell or
indirectly by inducing M-CSF or another of the above-mentioned cytokines or
another yet unknown cytokine having a direct effect on the acetyl-LDL uptake of
15 the macrophage cell.

12.4. Growth inhibitory effect of the mouse polypeptide of the invention on the colony stimulating activity of Wehi-3 conditioned medium

20 Colony-stimulating activity of bone marrow cells can be tested in vitro using a
standard CFU-GEMM agarose assay (Metcalf and Johnson, 1978) well known to
those skilled in the art. When enriched with the suitable growth factor (IL-3, GM-
CSF, G-CSF, M-CSF, erythropoietin), this assay system allows the proliferation of
a large variety of clonal cell populations from a total bone marrow cell mixture
25 including colonies of granulocytes, macrophages, megakaryocytes, eosinophils,
basophils, mast cells and, if the assay is conducted in the presence of
erythropoietin, even normoblasts and red cells (Bazil et al., 1983). When the
mouse polypeptide of the invention is added to the bone marrow cell mixture, no
cell colonies are formed using the CFU-GEMM assay either in the absence or
30 presence of erythropoietin indicating that the protein itself does not have any
intrinsic colony- stimulating activity on this cell population. When combined with
conditioned medium of Wehi-3 (ATCC TIB68) cells, described as containing an
active concentration of mouse IL-3 (Lee et al., 1982) (among other cytokines such
as GM-CSF, G-CSF, IL-1, etc.) allowing the growth of all the different cell
35 colonies mentioned above, the CSF activity of the conditioned medium was
significantly reduced. This demonstrates that the mouse polypeptide of the
invention exerts an inhibitory or antagonistic effect on the CSF potential of the
conditioned medium of Wehi-3 cells by interacting either indirectly or directly with
a single cytokine or a mixture of synergizing cytokines present in the protein
40 mixture.

5 12.5. Osteoblast growth-promoting effect of the mouse polypeptide of the invention using rat femur pre- and osteoblast enriched cell populations

10 The continuous remodelling of bone occurs as a coordinated succession of cell-mediated events involving an initial period of osteoclastic resorption followed by osteoblast-mediated bone formation. This process is highly regulated by different systemic factors and by cytokines.

15 Osteoblast proliferative activity of the mouse polypeptide of the invention was tested using femurs of 3-week-old male WISTAR rats. Osteoblastic cells were isolated from the cleaned and flushed femur bones by 5 sequential digestions of 30 minutes each with an enzyme mixture containing collagenase (Sigma), hyaluronidase (Sigma) and DNase (Boehringer Mannheim) at final concentrations of 0.5, 0.5 and 0.1 mg/ml, respectively. Subsequently, the cell pools of the first two and the last three enzymatic digestions were treated separately and are referred to as pre-osteoblasts and osteoblasts, respectively. Cell pools were washed in Ham F12-DMEM- Hepes (1:1, v/v) (HD) and plated in HD-10% FCS for 6 days. Thereafter, the osteoblastic cells were collected by trypsinization and plated in 48-well plates at 40,000 cells per well in HD - 1% FCS. Twenty-four hours later, the cells were washed and the medium was replaced by HD - 1% BSA for another 24 hours after which serial dilutions of the polypeptide of the invention were added. 25 Nineteen hours later the cells were labelled with ^3H -thymidine (1 μCi /well) for 6 hours and harvested for counting. The results (Fig. 21) point to a specific osteoblast proliferative-inducing activity of the composition containing the polypeptide of the invention.

30 12.6. Trypanocidal activity of the mouse polypeptide of the invention

35 The trypanocidal activity of the mouse polypeptide of the invention was measured using the following in vitro assay system: $2 \cdot 10^6$ /ml purified bloodstream forms of Trypanosoma brucei brucei or T. brucei rhodesiense, isolated 1 day before the first in vivo peak of parasitaemia, were incubated for 5 h in phosphate buffered saline (PBS), 1 % glucose, 1 % normal mouse serum (incubation medium) at 37°C with various concentrations of the recombinant mouse polypeptide of the invention. After 5 h of incubation, the number of living (= moving) parasites was assessed (counting chamber) and compared to the control wells in which only incubation medium was added to the trypanosomes. The spontaneous mortality in the control wells after 5 h was always lower than 10 %. 40 The T. brucei brucei AnTat 1.1 (EATRO 1125) pleomorphic bloodstream form

5 was provided by Dr. N. Van Meirvenne of the Institute for Tropical Medicine, Antwerp, Belgium, and the T. brucei rhodesiense Trp11 pleomorphic bloodstream form was provided by Dr. E. Bajyana Songa (Dept. Molecular Biology, Free University of Brussels, Belgium).

10 Incubation of purified bloodstream forms of T. brucei brucei and T. brucei rhodesiense for 5 h with the recombinant mouse polypeptide of the invention results in the mortality of a part of the parasites: 50 % of the animals are killed with 50 ng/ml of recombinant mouse polypeptide. In the same assay, 500 pg/ml of recombinant human or mouse TNF- α cause a 50 % mortality of T. brucei brucei or T. brucei rhodesiense (data not shown).

15

12.7. The mouse polypeptide of the invention enhances the mobility of LAK cells.

20 Lymphocytes activated killer (LAK) cells can be generated from murine spleen cells by stimulation with IL2. The mobility of the cells can then be tested by the use of a Transwell system (3 μ m membrane, Costar) wherein the migration of the cells through the membrane is measured after a fixed incubation method.

25 To test the effect of the mouse polypeptide of the invention on the mobility of LAK cells, F1 mice (Balb/c x C57b1) were sacrificed by cervical dislocation, and the spleen was removed aseptically, crushed with a syringe plunger and pressed through a syringe with 18G and a 23G needle into a petri-dish containing DMEM. Cell debris was removed by sedimentation, and the resulting cell suspension was depleted of B cells and macrophages by passing through a nylon wool column.

30 Thereto, 0.4g of nylon wool (Wako, Japan) was put in a 10 ml syringe and autoclaved. Just before applying the cells, the column was washed with DMEM - 5 % FCS and incubated for 1 h at 37°C. The spleen cells were resuspended in DMEM - 5 % FCS at a cell concentration of 10^8 cells/ml, loaded on the column (2 ml/run) and incubated for 45 min at 37°C. Subsequently, the nonadherent cell

35 fraction (these are all the non-B and non-macrophages cells) was recuperated from the column by washing the matrix with 10 ml DMEM - 5 % FCS. The cells were collected by centrifugation, washed and resuspended at 10^6 cells/ml in RPMI1640 - 10 % FCS - 50 μ M β -mercaptoethanol in the presence of 1000U/ml of IL2 and 25 ng/ml of the mouse polypeptide of the invention (LAK + IL2 + 30 kDa) for 7

40 days. Northern blotting analysis as well as cPCR studies demonstrated that the mRNA of the mouse polypeptide of the invention was induced around day 5 and

5 that the expression was linked with the generation of the cytotoxic LAK cell (data not shown).

After 7 days, the non-adherent cell population was washed away and the adherent LAK cells were removed from the plates by a short incubation with 0.01 % EDTA in PBS, washed and resuspended in RPMI1640 at a cell concentration of 10⁶ cells/ml. The LAK mobility assay was performed using a 24 well size Transwell cell culture chamber (Costar Europe, Badhoevedorp, The Netherlands) essentially as described by the supplier. In the cluster well, 600 μ l of RPMI1640 alone (negative control) or enriched with 50, 25, 12.5, 6.25, or 3.12 ng of the mouse polypeptide of the invention was added. In the Transwell, 100 μ l of the LAK cell suspension (= 10⁵ cells) either generated with IL2 alone (LAK) or with IL2 and 50 ng/ml of the mouse polypeptide of the invention (LAK + 30kDa) was added. After 4 h incubation at 37°C, those cells which migrated through the membrane to the cluster well, were counted. The results of such an experiment are given in Table IV and clearly demonstrate that the LAK cells generated in the presence of the mouse polypeptide of the invention in the cluster well also enhances the mobility of the LAK cells.

Table IV

concentration ^a	LAK + IL2		LAK + IL2 + 30kDa	
	30kDa		30kDa	
50 ng/ml	86	66	143	104
25 ng/ml	105	96	167	139
12.5 ng/ml	111	58	162	183
6.25 ng/ml	118	48	187	138
3.12 ng/ml	79	79	201	136
0 ng/ml		58		137

a: concentration of the mouse polypeptide of the invention (30 kDa) in the cluster well during the mobility assay.

12.8. Intrafootpath (I. fp.) injection of the mouse polypeptide of the invention enhances the immunoresponsiveness of lymph node cells in mice.

To test the in vivo effect of the mouse polypeptide of the invention, F1 (Balb/c x C57b1) mice were injected intrafootpath (i.fp.) with 50 ng of the mouse

5 polypeptide of the invention in 50 μ l of RPMI1640, or the equivalent volume of PBS in 50 μ l RPMI1640/mouse. Twenty four hours later, the popliteal lymph node cells were isolated and resuspended in RPMI1640 - 50 μ M β -mercaptoethanol - 1 % normal mouse serum (NMS) at a cell concentration of 2.10⁶ cells/ml.

10 Subsequently, the cells were plated in a 96-well microtiter plate at 4.10⁵ cells/200 μ l/well in the same medium and stimulated for 24-48 h with 3 μ g/ml ConA (T-Cell stimulation), or 10 μ g/LPS (B-Cell stimulation). ³H-Thymidine was added (1 μ Ci/well) for another 18 h and the cells were harvested and counted. The results are expressed in counts per minute (cpm) incorporated and are given in Table V.

15

Table V: ConA LPS stimulated LNC proliferation is enhanced after the in vivo ifp injection of the mouse polypeptide of the invention.

	LNC proliferation (cpm x 10 ⁻³)	
	ConA	LPS
<u>experiment 1</u>		
- PBS treated	63	2
- rec prot treated	141	5
<u>experiment 2</u>		
- PBS treated	9	N.D.
- rec prot treated	153	N.D.

20 The results clearly demonstrate that the LNC from mice treated with the mouse polypeptide of the invention are sensitized to respond more efficiently towards T- and B-cell mitogens. The mouse polypeptide of the invention might therefore function directly as a costimulatory factor for T- and B-cells or more indirectly induce a T- and B-cell stimulatory factor.

25

12.9 Intraperitoneal injection of the mouse polypeptide of the invention augments the generation of suppressive macrophages.

30 To test the effect of the mouse polypeptide of the invention on peritoneal macrophages, F1 mice (Balb/c x C57bl) were injected intraperitoneal (i.p.) with either 50 ng of the mouse polypeptide of the invention in 200 μ l RPMI1640 or the

5 equivalent volume of PBS in RPMI1640. Twenty four hours later, the peritoneal exudate cells (PEC) were isolated by an i.p. wash with 10 ml of RPMI1640 per mouse, collected by centrifugation and resuspended at a concentration of 2.10^6 cells/ml in RPMI1640 - 50 μ M β -mercaptoethanol - 1 % NMS. PEC batches contaminated with erythrocytes were discarded.

10

10^4 , 2.10^4 , or 3.10^4 PEC were cocultured for 24 hours with normal lymph node cells from normal F1 mice that were seeded in 96 microtiter plates at a cell concentration of 4.10^9 cells/200 μ l/well in RPMI1640 - 1 % NMS - 3 μ g/ml ConA in the absence (experiment 1) or in the presence of 10 μ g/ml Indomethacin. After 15 an additional 18 h pulse with 3 H-thymidine (1 μ Ci/well), the cells were harvested and counted.

The results summarised in table VI are expressed as % suppression relative to the proliferation of LNC without PEC.

20

Table VI: The ConA induced proliferation of LNC is reduced by coculture with PEC isolated from mice injected interperitoneal with the mouse polypeptide of the invention.

	% suppression of LNC ConA proliferation		
	2.5 % PEC	5 % PEC	7.5 % PEC
<u>experiment 1</u>			
- PBS treated	0	38	97
- rec prot treated	60	99	99
<u>experiment 2 (+ indomethacin)</u>			
- PBS treated	0	0	0
- rec prot treated	0	0	84

25

From these results the following conclusions can be drawn:

(i) PECs from PBS and the mouse recombinant protein of the invention treated animals are suppressive on LNC. The suppressive activity of the PECs of the animals treated with the mouse polypeptide in the invention is, however, more pronounced when compared with the control animals.

30

(ii) The suppressive activity of PECs may be mediated via Prostaglandin (PG) release of macrophages presence in the cell mixture. To test this possibility,

5 the PECs were cocultured with ConA stimulated LNC in the presence of PG
synthesis inhibitor Indomethacin (experiment 3). From these results it is clear that
the PECs from the control animals as well as from the animals treated with the
mouse polypeptide of the invention mediate their suppressive activity via PG
release. However, the mouse polypeptide of the invention specifically modulates
10 PECs that mediate a part of their suppressive activity via a PG-independent
mechanism.

15

- Adams, D.O., Hamilton, T.A. (1984) The cell biology of macrophage activation. *Ann. Rev. Immunol.* 2:283-318.
- 10 Atherton, E. and Sheppard, R.C. (1989) Solid Phase Peptide Synthesis: A Practical Approach.
Rickwood, D. and Hames, B.D. eds. IRL Press (Oxford).
- 15 Bazill, G.W., Haynes, M., Garland, J., Dexter, T.M. (1983) Characterization and partial purification of a haemopoietic cell growth factor in WEHI-3 cell conditioned medium.
Biochem. J. 210:747-759.
- 20 Billiau, A. (1987) Interferons and inflammation.
J. Interferon Res. 7:559-567.
- Capecchi, MR. (1989) The new mouse genetics: altering the genome by gene targeting.
Trends Genet. 5:70-6.
- 25 Caput, D., Beutler, B., Hartog, K., Thayer, R., Brown-Shimer, S., Cerami, A. (1986) Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators.
Proc. Natl. Acad. Sci. USA 83:1670-1674.
- 30 Chirgwin, J.M., Przybyla, A.E., MacDonald, R.J., Rutter, W.J. (1979) Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.
Biochemistry 18: 5294-5299.

- 5 Davatelis, G., Tekamp-Olsen, P., Wolpe, S.D., J., Hermesen, K., Leudke, C., Gallegos, C., Coit, D., Merryweather, J., Cerami, A. (1988) Cloning and characterization of a cDNA for murine macrophage inflammatory protein (MIP), a novel monokine with chemotactic and chemokinetic properties. J. Exp. Med. 167:1939-1949.
- 10 Durum, S.K., Schmidt, J.A., Oppenheim, J.J. (1986) Interleukin-1: an immunological perspective. Ann. Rev. Immunol., 3:263-287.
- 15 Fournay, R.M., Miyakoshi, J., Day R.S. III, Paterson, M.C. (1988) Northern blotting: efficient RNA staining and transfer. FOCUS 10:5-6.
- 20 Fransen, L., Muller, R., Marmenout, A., Tavernier, J., Van Der Heyden, J., Kawashima, E., Chollet, A., Tizard, R., Van Heuverswijn, H., Van Vliet, A., Ruyschaert, M.R., Fiers, W. (1985) Molecular cloning of mouse tumour necrosis factor cDNA and its eukaryotic expression. Nucleic Acids Res. 13:4417-4429.
- 25 Gerard, G.F. and Miller, K. (1986) Comparison of glyoxal and formaldehyde gels for sizing mRNAs. FOCUS 8:5-6.
- 30 Gheysen, D. and Fiers, W. (1982) Expression and excretion of human fibroblast β 1-interferon in monkey cells after transfection with a recombinant SV40 plasmid vector. J. Mol. Appl. Genet. 1:385-394.
- 35 Gluzman, Y. (1981) SV40-transformed simian cells support the replication of early SV40 mutants. Cell 23:175-182.
- 40 Gordon, J.W. (1989) Transgenic animals. Int. Rev. Cytol. 115:171-229.
- Graham, F.L. and van der Eb, A.J. (1973) A new technique for the assay of infectivity of human adenovirus 5 DNA.

- 5 Virology 52:456-467.
- Hanahan, D. (1983) Studies on transformation of *E. Coli* with plasmids.
J. Mol. Biol. 166:557-580.
- 10 Hanahan, D., and Meselson, M. (1980) Plasmid screening at high colony density.
Gene 10:63-67.
- Harlow, E., Lane, D. eds. Antibodies: A Laboratory Manual (1988) Cold Spring Harbor Laboratory, Cold Spring Harbour Press.
- 15 Houbenweyl (1974) Methode der organischen chemie edited by E. Wunsch, vol. 15-I and II. THIEME, Stuttgart 1974.
- 20 Ishibashi, S., Inaba, T., Shimano, H., Harada, K., Inoue, I., Mokuno, H., Mori, N., Gotoda, T., Takaku, F., Yamada, N. (1990) Monocyte colony stimulating factor enhances the uptake and degradation of acetylated low density lipoproteins and cholesterol esterification in human monocyte derived macrophages.
J. Biol. Chem. 265:14109-14117.
- 25 Izant, J.C. and Weintraub, H. (1984) Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis.
Cell 36:1007-1015.
- 30 Izant, J.C. and Weintraub, H. (1985) Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA.
Science 229:345-52.
- 35 Julius, M.H., Simpson, E., Herzenberg, L.A. (1973) A rapid method for the isolation and functional thymus-derived murine lymphocytes.
Eur. J. Immunol. 3:645-649.
- 40 Kahn, M., Kolter, M., Thomas, C., Figurski, D., Meyer, R., Remaut, E., Helinski, D.R. (1979) Plasmid cloning vehicles derived from plasmids ColE1, F, R6K, and RK2.
Meth. Ezymol., 68:268-280.

- 5 Kearney, J.F., Radbruch, A., Liesegang, B., Rajewsky, K. (1979) A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.
J. Immunol. 123:1548-1550.
- 10 Kishimoto, T. and Hirano, T. (1988) Molecular regulation of B lymphocyte response.
Annu. Rev. Immunol. 6:485.
- 15 Kyte, J. and Doolittle, RF. (1982) A simple method for displaying the hydropathic character of a protein.
J. Mol. Biol. 157:105-132.
- 20 Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature 227:680-685.
- 25 Lee, J.C., Hapel, A.J., Ihle, J.N. (1982) Constitutive production of a unique lymphokine (IL3) by the Wehi-3 cell line.
J. Immunol., 128:2393-2398.
- 30 Luckow, V.A. and Summers, M.D. (1988) Trends in the development of baculovirus expression vectors.
Biotechnology 6:47-55.
- 35 Maniatis, T., Fritsch, E.F., Sambrook, J. (1982) in Molecular cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.
- 40 Matsuura, Y., Possee, R.D., Overton, H.A. Bishop, D.H.L. (1987). Baculovirus expression vectors: the requirements for high level expression of proteins, including glycoproteins.
J. Gen. Virol. 68:1233-1250.
- 40 McCutchan, J.H. and Pagano, J.S. (1968) Enhancement of the infectivity of Simian virus 40 deoxyribonucleic acid with diethyl aminoethyl-dextran.
J. Natl. Cancer Inst. 41:351-356.

- 62
- 5 Metcalf, D. and Johnson, G.R. (1978) Production of spleen and lymph node cells of conditioned medium with erythroid and other hemopoietic colony stimulating activity.
J. Cell Physiol. 96:31-42.
- 10 Miltenyi, S., Muller, W., Weichel, W., and Radbruch, A. (1990) High Gradient Magnetic Cell Separation with MACS
Cytometry 11:231-238.
- Moss, B. and Flexner (1987) Vaccinia virus expression vectors.
- 15 Ann. Rev. Immunol. 5:305-324.
- Mossman, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
J. Immunol. Methods 65:55-63.
- 20 Mullis, KB. and Faloona, FA. (1987) specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction.
Methods Enzymol. 155:335-350.
- 25 Old and Primrose (1981)
Principles of Gene Manipulation (2 ed. 1981).
- Old, L.J. (1985) Tumor necrosis factor.
Science 30:630-632.
- 30 Panayatos, N. in "Plasmids: A Practical Approach".
(ed. K.G. Hardy, IRL Press) pp. 163-176
- Perrson, M.A.A., Caothien, R.H., Burton, D.R. (1991) Generation of diverse high affinity human monoclonal antibodies by repertoire cloning.
Proc. Natl. Acad. Sci. 88:2432-2436.
- 35 Quesenberry, P.J. (1986) Synergistic Hematopoietic growth factors.
Int. J. Cell Cloning 4:3-15.
- 40 Rasmussen, H.H., Van Damme, J., Bauw, G., Puype, M., Gesser, B., Celis, J.E. Vandekerckhove J. (1991) Protein-electroblotting and microsequencing in

- 5 establishing integrated human protein databases. In *Methods in Protein Sequence Analysis*. Jornvall, Hoog, Gustavsson (eds.) Bichhauser Verlag, Basel, 103-114.
- Ruff, M.R. and Gifford, G.E. (1981) in *Lymphokines* (Pick, E., ed.) vol 2, pp 235-275, Academic Press, New York.
- 10 Saiki, R.K., Scharf, S., Faloona, F., Mullis, K.B., Horn, G.T., Erlich, H.A., Arnheim, N. (1985) Enzymatic amplification of β -globulin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. *Science* 230:1350-1354.
- 15 Schagger, H. and von Jagow, G. (1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range of 1 to 100 kDa. *Anal. Biochem.* 166:368-379.
- 20 Smith, G.E., Summers, M.D., Fraser, M.J. (1983) Production of human beta interferon in insect cells infected with a baculovirus expression vector. *Mol. Cell. Biol.* 3:2156-2165.
- 25 Smith, G.E., Ju, G., Ericson, B. L., Moshera, J., Lahm, H., Chizzonite, R. Summers, M.D. (1985) Modification and secretion of human interleukin 2 produced in insect cells by a baculovirus expression vector. *Proc. Natl. Acad. Sci. USA* 82:8404-8408.
- 30 Stunnenberg, H.G., Lange, H., Philipson, L. van Miltenburg, R.T. van der Vliet, P.C. (1988) High expression of functional adenovirus DNA polymerase and precursor terminal protein using recombinant vaccinia virus. *Nucleic Acids Res.* 16:2431-2444.
- 35 Towbin, H., Staehlen, T., Gordon, J. (1979) Electrophoretic transfer of proteins from acrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc. Natl. Acad. Sci.* 76:4350-4354.
- 40 Twigg, A.J. and Sherratt, D. (1980) Trans-complementable copy-number mutants of plasmid ColE1. *Nature* 283(5743):216-218.

- 64
- 5 Unanue, E.R. (1989) in *Fundamental Immunology* (Paul, W.E. ed) Raven Press, New York, pp 95.
- 10 Urdea, MS., Merryweather, JP., Mullenbach, GT., Coit, D., Heberlein, U., Valenzuela, P., Barr, PJ. (1983) Chemical synthesis of a gene for human epidermal growth factor urogastrone and its expression in yeast. *Proc. Natl. Acad. Sci. U.S.A.* 80(24):7461-7465.
- 15 Van Damme, J., De Ley, M., Van Snick, J., Dinarello, C.A., Billiau, A. (1987) The role of interferon-beta1 and the 26 kDa protein (interferon-beta2) as mediators. *J. Immunol.* 139:1867-1872.
- 20 Van Fleteren, J.R., Raymackers, J., Van Bun, S.M. Meheus, L.A. (1992) Peptide mapping and microsequencing of proteins separated by SDS-PAGE after limited *in situ* acid hydrolysis. *Biotechniques* 12:1-6.
- 25 Van Snick, J., Cayphas, S., Vink, A., Uyttenhove, C., Coulie, P.G., Rubira, M.R., Simpson, R.J. (1986) Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. *Proc. Natl. Acad. Sci. USA* 83:9676-9683.
- 30 Von Heijne, G. (1986) A new method for predicting signal sequence cleavage sites. *Nucleic Acids Res.* 14:4683-4690.
- 35 Wagner, E.F., Keller, G., Gilboa, E., Ruther, U., Stewart, C.L., (1985) Gene transfer into murine stem cells and mice using retroviral vectors. *Cold Spring Harbor Symp. Quant. Biol.* 50:961-700.
- 40 Wickstrom, E.L., Bacon, T.A., Gonzales, A., Freeman, D.L., Lyman, G.H., Wickstrom, E. (1988) Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. *Proc. Natl. Acad. Sci. USA* 85:1028-1032.

- 5 Yoshimura, T., Matsushima, K., Tanaka, S., Robinson, E.A., Appella, E. ,
Oppenheim, J.J., Leonard, E.J. (1987) Purification of a human monocyte-derived
neutrophil chemotactic factor that has peptide sequence similarity to other host
defense cytokines.
Proc. Natl. Acad. Sci. USA 84:9233-9237.
- 10 Ziegler-Heitbrock, H.W., Thiel, E., Futterer, A., Herzog, V., Wirtz, A. (1988)
Establishment of a human cell line (Mono Mac6) with characteristics of mature
monocytes.
Int. J. Cancer 41:456-461.

15

1. Polypeptide containing in its peptidic chain
 - the amino acid sequence of 311 amino acids of Figure 3,
 - or a fragment of this sequence, with said fragment being such that it is
- 10 liable to produce antibodies capable of forming a complex with the amino acid sequence of Figure 3,
 - or an amino acid sequence having a percentage of homology of at least 50%, preferably 75%, and advantageously 90% with the amino acid sequence of Figure 3,
- 15
 - or a sequence liable to form a complex with antibodies raised
 - * against the amino acid sequence of Figure 3
 - * or against pep1(m)
 - * or against pep2(m)
 - * or against pep3(m).
- 20
2. Polypeptide according to claim 1 containing in its peptidic chain
 - the amino acid sequence of 311 amino acids of Figure 2,
 - or a fragment of this sequence, with said fragment being such that it is
- 25 liable to produce antibodies capable of forming a complex with the amino acid sequence of Figure 2
 - or an amino acid sequence having a percentage of homology of at least 50%, preferably 75%, and advantageously 90% with the amino acid sequence of Figure 2,
- 30
 - or a sequence liable to form a complex with antibodies raised
 - * against the amino acid sequence of Figure 2
 - * or against pep1(h)
 - * or against pep2(h)
 - * or against pep3(h).
- 35
3. Polypeptide according to claim 1, characterized by the fact that it is constituted by the sequence represented in Figure 3, extending from the extremity constituted by amino acid at position (1) to the extremity constituted by amino acid at position (311), or that it contains at
- 40 least one of the following peptides:
 - * Cys-Ser-Trp-Lys-Gly-Ser-Gly-Leu-Thr
 - * Val-Glu-Trp-Met-Tyr-Pro-Thr-Gly-Ala-Leu-Ile-Val-Asn-Leu-Arg-Pro-Asn-Thr-Phe-Ser-Pro-Ala

- 5 * Asp-Ser-Ser-Gly-Ala-Asn-Ile-Tyr-Leu-Glu-Lys-Thr-Gly-Glu-Leu-Arg-Leu-Leu-Val .
- * Leu-Glu-Gln-Gly-Gly-Leu-Phe-Val-Glu-Ala-Thr-Pro-Gln-Gln-Asp-Ile
- * Arg-Arg-Thr-Thr-Gly-Phe-Gln-Tyr-Glu-Leu
- * Leu-Ser-Ala-Pro-Cys-Arg-Pro-Cys-Ser-Asp-Thr-Glu-Val-Leu-Leu-Ala
- 10 * Arg-Gln-Lys-Ser-Arg-Val-Phe
- * Cys-Gly-Val-Arg-Pro-Gly-His- Gly
- * Phe-Leu-Phe-Thr-Gly-His
- * Leu-Gly-Cys-Ala-Pro-Arg-Phe
- * Asp-Phe-Gln-Arg-Met-Tyr-Arg

15

4. Polypeptide according to claim 2, characterized by the fact that it is constituted by the sequence represented in Figure 2, extending from the extremity constituted by amino acid at position (1) to the extremity constituted by amino acid at position (311).

20

5. Muteins deriving from anyone of the polypeptides of claims 1 to 4, containing modifications consisting of substitutions and/or deletions and/or additions of one or several amino acids, insofar that said modifications do not alter the hydropathicity profile such as defined by Kyte and Doolittle (1982) and such as represented in Figure 6a and 6b.

25

6. Polypeptide according to any one of claims 1 to 5 presenting at least one of the following properties:

30

- promoting the incorporation of ^3H -thymidine in rat femur pre- and osteoblasts cells, in 3-week-old mice thymocytes, in splenic cells or lymph node cells, advantageously upon co-stimulation with IFN- γ ,

- promoting the incorporation of ^3H -thymidine in thymocytes, advantageously upon co-stimulation with IL-4,

35

- promoting the activation or cytotoxicity or mobility of LAK cells.

- promoting the recruitment of suppressive peritoneal exudate cells upon injection in vivo,

- promoting the generation of immunocompetent lymph node cells, preferentially after ConA, PHA or LPS induction, upon in vivo intrafootpath injection,

40

- exerting a trypanocidal or trypanolytical activity on the pleomorph bloodstream trypanosomes in vitro.

- 5 7. Amino acid sequence constituted by a polypeptide according to anyone of claims 1 to 6, and a protein or a heterologous sequence with respect to said polypeptide, with said protein or heterologous sequence comprising, for instance, from about 10 to about 100 amino acids.
- 10 8. Nucleic acid characterized by the fact that it comprises or is constituted by:
- a nucleotide sequence which is effectively homologous with any of the nucleotide sequence coding for the polypeptides according to any one of claims 1 to 6,
 - 15 - a nucleotide sequence liable to hybridize with anyone of the nucleotide sequence coding for the polypeptides according to anyone of claims 1 to 6,
 - or a nucleotide sequence which, further to translation or further to transcription and to translation, leads to anyone of the polypeptide according to claims 1 to 6,
 - 20 - or the complementary sequences of the above-mentioned nucleotide sequences.
9. Nucleic acid according to claim 8, which comprises or is constituted by:
- a nucleotide sequence which is effectively homologous with any of the
 - 25 nucleotide sequences of Figure 1,
 - a nucleotide sequence liable to hybridize with the complementary strand of the nucleotide sequence of Figure 1,
 - the nucleotide sequence of Figure 1,
 - the complementary sequences of the above-mentioned sequences.
 - 30
10. Nucleic acid according to claim 8, which comprises or is constituted by:
- a nucleotide sequence which is effectively homologous with any of the nucleotide sequences of Figure 2,
 - a nucleotide sequence liable to hybridize with the
 - 35 complementary strand of the nucleotide sequence of Figure 2,
 - the nucleotide sequence of Figure 2,
 - the complementary sequences of the above-mentioned sequences.
11. Nucleic acid according to claim 8, which comprises or is constituted by:
- 40 a nucleotide sequence which is effectively homologous with any of the nucleotide sequences of Figure 3,
 - a nucleotide sequence liable to hybridize with the

- 5 complementary strand of the nucleotide sequence of Figure 3,
- the nucleotide sequence of Figure 3,
- the complementary sequences of the above-mentioned sequences.

12. Recombinant nucleic acid containing at least one of the nucleotide
10 sequences of anyone of claims 8 to 11 combined with or inserted in a heterologous nucleic acid.

13. Recombinant vector particularly for cloning and/or expression,
15 comprising a vector sequence, notably of the type plasmid, cosmid, phage, or virus DNA and a recombinant nucleic acid according to anyone of claims 8 to 12, inserted in one of the nonessential sites for its replication.

14. Recombinant vector according to claim 13, containing necessary elements
20 to promote the expression in a cellular host of polypeptides coded by nucleic acids according to anyone of claims 8 to 12, inserted in said vector and notably a promoter recognized by the RNA polymerase of the cellular host, particularly an inducible promoter and possibly a sequence coding for transcription, termination, and possibly a signal sequence and/or an anchoring sequence.

25 15. Recombinant vector according to claim 13, containing the elements enabling the expression of a nucleotide sequence according to anyone of claims 8 to 11, as a mature protein or as part of a fusion protein, the fusion moiety which is used in the fusion protein being part of a nonhomologous protein (such as mTNF)
30 chosen to optimize the expression of a fusion protein.

16. Cellular host chosen from among bacteria such as E.coli or chosen from among eukaryotic organisms, such as COS cells, baculovirus or vaccinia virus, which is transformed by a recombinant vector according to anyone of claims 13 to
35 15 and containing the regulatory elements enabling the expression of the nucleotide sequence coding for the polypeptide according to anyone of claims 1 to 7 in this host.

17. Expression product of a nucleic acid expressed by a transformed cellular
40 host according to claim 16.

5 18. Antibody characterized by being specifically directed against a polypeptide according to anyone of claim 1 to 7.

19. Nucleotidic probe, hybridizing with any of the nucleic sequences according to anyone of claims 8 to 11.

10

20. Process for preparing a recombinant polypeptide according to anyone of claims 1 to 7, comprising the following steps:

- the culture in an appropriate medium of a cellular host which has previously been transformed by an appropriate vector containing a nucleic acid according to anyone of claims 8 to 11, and
- the recovery of the polypeptide produced by the above-said transformed cellular host from the above-said culture medium or from the cellular host.

15

21. Process for detecting the capacity of a molecule to behave as a ligand or as a receptor with respect to a polypeptide according to anyone of claims 1 to 6, characterized by:

- contacting the molecule with a cellular host which has previously been transformed by a vector itself modified by an insert coding for said polypeptide, this host carrying on its surface one or several specific sites of this polypeptide, possibly after induction of the expresion of this insert, with said contacting being carried out under conditions enabling binding between at least one of these specific sites and said molecule to be formed if it happens to present an affinity for said polypeptide,
- detecting the possible formation of a complex of the type ligand-polypeptide or receptor-polypeptide.

20
30

22. Immunogenic composition containing, as active substance, at least one of the polypeptides of Figure 2, or anyone of the peptides pep1(h), pep2(h) or pep3(h).

35

23. Pharmaceutical compositions containing, as active substance, at least anyone of the polypeptides of claims 1 to 6 or of the antagonists of the polypeptides above-defined as antitumor compounds, or antiinflammatory compounds, as growth activators of T-cells and B-cells, as bone repair compounds, as inducer of immunosuppressive cells as inhibitors of anti-colony stimulating factor; or as trypanocidal agents; or part of the polypeptides of the invention, capable of binding to the receptor defined above.

40

5 24. Antisense oligonucleotides or antisense mRNA derived from the
nucleotide sequences of anyone of claims 8 to 11.

10 25. Nonhuman mammalian transgenic animal which contains, in its genome,
a nucleic acid sequence according to anyone of claims 8 to 11, and which can be
used to study the effects of pharmacological compositions and to prepare different
cell types from transgenic animals which express the nucleotide sequence according
to anyone of claims 8 to 11 in a constitutive or inducible way.

15 26. "Knock-out" nonhuman mammalian transgenic animal in which the
natural gene, effectively homologous with any one of the nucleotide sequences
according to anyone of claims 8 to 11, is rendered nonfunctional, for instance by
homologous recombination, with said animal being suitable for the study of the
possible loss of functions or the possible restoration effects caused by the
reintroduction into the animals of the polypeptides according to anyone of claims 8
20 to 11.

25

GTACCTGCA GTGATGGGG TGGGGGAGG TGCACTCCTA GAGCAGAGG GGTGGGTGG
 GGCAGTCTCC AAGCTCCGAA ATGCACCTCC ACCAGATCTT GAGCCTCAGG GTGATGTAC
 TTGATGTGCT GGGCAAGGTC CTGGCTCCAG GCTTTCGATG GGTGGGTGC TCTGAACACA
 TCCTTACAAT GAAACTACCT TCAGTGGTCA CTGTCAATCGC CTTCAGTTC TTCAGACCTT
 CACCTTGTC CCAGCTTTCC TGGGCTGGG GCTGGGCTCC ACCTGCCCTT GCCGGTACT
 TCCGTCCCTG CAGACTCACA ATTTCAAAG CCTCTCCTC CTGGAAGGTA TCTTGGCTGG
 CCCAGTTAT CAGACTTGA CAGTCTGTTT GCAAGTCTC CTGGATGCTG CGCTCGGCTC TGGAACTGAC
 AAAAGGGAC AAGGCCAAGC TTCCCCACCG CTGGATGCTG GCAGCACACA GAAGCCAGCT TTGCCATCGC
 ACCAGGGCTC TCGGGCAGG CCACTGACCC GCAGCACACA GAAGCCAGCT TTGCCATCGC
 AGCGGGACCC(C)GGCGGGCCASSTCCG CCTCTCCTG CAGTCCGGGCTCAGCTTTGGCACTCC
 TCTGGCTCCC CTCTCTGGC CTGAGTCTCT AGGCGCTCC CAGTCCGGGCTCAGCTTTGGCACTCC
 GCTGTCCCC CAACTGGGTC AGCAGTCTG TGGCGCGGT TGGCGCGGT GGAAGGCGCC
 GACTCCGAG AACACACTCG AGCAGTCTG TCCGCGAGT ATCTGCTCC GCGGCGAGG
 GGTGGGGCG GATTTGGC AAATCTGCG AGAGTCTG AGGTGCTG CAACATCCA CCATGCGAG
 GTTGCTACTG ATACCCAGAG TCGGGGGCC CACCCGGCCC CGCGTATCC GAGCGAGGAG
 GACGTCCCA CCCCAGAAC CACCCGGCCC GTCTCCGGG AGGAGGGAGG GAAGCCGGG
 TCGGCAGAG CCGCGCGCG GCCTCCCGG CGGCTGCGC GTCTCCGGG ACTCCCGAG CACCAACTCT
 TCACCGCCG GCGCGCCCG ATCGCCCTG ATCACCSCC GCTGGCGAGG CGCGGGGAC
 GCGGAACCG GCGCGCCCG AGCTCCTT ACCGCTCCG CCGGGGCTG CCGCAGGAT
 CCAGAACCG GCGCGCCCG AGCTCCTT ACCGCTCCG CCGGGGCTG CCGCAGGAT
 GGGCGCAGG ATGGGCGCA GATGCGGCC CCGGCACCG CCGCGGGG TCTGCGGGG
 GCGACCGCG CTGCGTCCG CCACTACTG GGGGTCTCG GTTTCGCGC CGCCTCGC
 TTGCAACCC TCCGGCCCC GACTCCGCTT TCCAGGCGG GCTCTTCCCT CCGACCCCG
 CTCGCGCCC GCGCGGCC CCTCCTCTG CAGCGCCCC CGCCCGCG CCGCGCGCC
 CGATTGCTG CTGACTCGT GTCTGCGCTT CCGCGCGG CCGCGGGAG GAGTTCCG
 CGCGGGCGG GGTGCGGGG GGGTCCGG GCGGGCGG GCGCGGGT GCGCCACCC
 CCAAGCTAG CCGCGCGG CCGACTCGA CTCGCCAAT TCAGAGGCTC GCGCGCGG
 GCGGGCGG AGCTTGGC GCGGCTCCG CCGCGCGG TGGCGGGG GCGCGCGG
 GGACGCGG GCGCGCGG GACTCGAG GACTCGAG CCGCGCGG CCGCGCGG
 CTCGCGGCT CCGGGTCTG CTCCGGGGT CCGGACCGG GCGCGGGG GCGAGCGG

Figure 1

```

CGCCAGAGC ATG CCG GGC GCG CCG GCG GCG GCG TGG GGC CGC GCG GCG GCG CAG 1851
      MET Arg Gly Ala Ala Arg Ala Ala Trp Gly Arg Ala Gly Gln
      5      10
CCG TGG CCG CGA CCC CCC GCG GGC CCG CCC CCG CCG CTC CCG 1899
Pro Trp Pro Arg Pro Ala Pro Gly Pro Pro Pro Pro Pro Leu Pro
15      20      25      30
CTG CTG CTC CTG CCG GCG GCG CTG GCG GCG GCG GCG GCG CAG 1947
Leu Leu Leu Leu Ala Gly Leu Leu Gly Ala Gly Ala Gln
35      40      45
TAC TCC AGC GAC CCG TGC AGC TGG AAG GCG AG GTGAGTGTGC GCGGCGCGAC 1999
Tyr Ser Ser Asp Arg Cys Ser Trp Lys Gly Ser
50      55
CCCGGCCCGG CCCCTCCCC TCGCGTCCCC TCCCGTCCCG GGC CGGCCGA GCGTGCGGGG 2059
GCGCGGCCCG GCGCGGCCG GCGCGGCCG CTCCGGGGC CGCTCTCCAG GCCCAGTCCG 2119
GTGCCCGCTG TCCCGCGCCC CCGGTTCTAG A----- 2150

GAGCTCCGGG CCTGGCTGAC AGTGTCTCTC CTCTGCAG C GGS CTG ACG CAC GAG 2204
      Gly Leu Thr His Glu
      60
GCA CAC AGG AAG GAG GTG GAG CAG GTG TAT CTG CCG TGT GCG GCG GGT 2252
Ala His Arg Lys Glu Val Glu Gln Val Tyr Leu Arg Cys Ala Ala Gly
65      70      75
GCC GTG GAG TGG ATG TAC CCA ACA GGT GCT CTC ATC GTT AAC CTG CCG 2300
Ala Val Glu Trp MET Tyr Pro Thr Gly Ala Leu Ile Val Asn Leu Arg
80      85      90
CCC AAC ACM TTC TCG CCT GCC CCG CAC CTG ACC GTG TGC ATC AGG TCC 2348
Pro Asn Thr Phe Ser Pro Ala Arg His Leu Thr Val Cys Ile Arg Ser
95      100      105      110

```

Figure 1 (con't 1)

TTC ACG GAC TCC TCG GGG GCC AAT ATT TAT TTG GAA AAA ACT GGA GAA 2396
 Phe Thr Asp Ser Ser 115 Gly Ala Asn Ile Tyr Leu Glu Lys Thr Gly Glu
 CTG AGA CTG CTG GTA CCA GAC GGG GAC GGC AGG CCC GGC CGG GTG CAG 2444
 Leu Arg Leu Leu Val Pro Asp Gly Asp Gly Arg Pro Gly Arg Val Gln
 TGT TTT GGC CTG GAG CAG GGC GGC CTG TTC GTG GAG GCC ACG CCG CAG 2492
 Cys Phe Gly Leu Glu Gln Gly Thr Phe Val Glu Ala Thr Pro Gln
 CAG GAT ATC GGC CGG AGG ACC ACA GGC TTC CAG TAC GAG CTG GTT AGG 2540
 Gln Asp Ile Gly Arg Arg Thr Thr Gly Phe Gln Tyr Glu Leu Val Arg
 AGG CAC AGG GCG TCG GAC CTG CAC GAG CTG TCT G GTGAGTGTCC TGCCTG 2590
 Arg His Arg Ala Ser Asp Leu His Glu Leu Ser
 175 180 185
 ----- CCTCCAGCAC GTGCCGCCAA CTCACATTG AAGTGGCGTT 2630
 GGTCACAAAG GTGCCCTGAC GTGGACACCC TCCCTGACTT GGCTTTGCTG AGTGTGAGGA 2690
 TCCTTTGACG GTGGTGGCG GCGTTCCAGA GCCTGTCCCG TCCAGGCTGC TTCCTGACTC 2750
 TGCCTTTCTT CTCCAG CG CCG TGC CGT CCC TGC AGT GAC ACC GAG GTG CTC 2801
 Ala Pro Cys Arg Pro Cys Ser Asp Thr Glu Val Leu
 190 195
 CTA GCC GTC TGC ACC AGC GAC TTC G GTGAGTGTCT CCTCGGCAGC TTCFACC 2853
 Leu Ala Val Cys Thr Ser Asp Phe
 200 205

Figure 1 (con't 2)

```

----- CCCCATCTCC TTCCCCGCAC AG CC GTT CGA GGC TCC 2889
              Ala Val Arg Gly Ser 210
ATC CAG CAA GTT ACC CAC GAG CCT GAG CGG CAG GAC TCA GCC ATC CAC 2937
Ile Gln Gln Val Thr His Glu Pro Glu Arg Gln Asp Ser Ala Ile His
CTG CGC GTG AGC AGA CTC TAT CGG CAG AAA AGC AGG GTC TTC GAG CCG 2985
Leu Arg Val Ser Arg Leu Tyr Arg Gln Lys Ser Arg Val Phe Glu Pro
              230
GTG CCC GAG GGT GAC GGC CAC TGG CAG GGG CGC GTC AGG ACG CTG CTG 3033
Val Pro Glu Gly Asp Gly His Trp Gln Gly Arg Val Arg Thr Leu Leu
              245
GAG TGT GGC GTG CGG CCG GGG CAT GGC GAC TTC CTC TTC ACT GGC CAC 3081
Glu Cys Gly Val Arg Pro Gly His Gly Asp Phe Leu Phe Thr Gly His
              260
ATG CAC TTC GGG GAG GCG CGG CTC GGC TGT GCC CCA CGC TTC AAG GAC 3129
MET His Phe Gly Glu Ala Arg Leu Gly Cys Ala Pro Arg Phe Lys Asp
              275
TTC CAG AGG ATG TAC AGG GAT GCC CAG GAG AGG GGG CTG AAC CCT TGT 3177
Phe Gln Arg MET Tyr Arg Asp Ala Gln Glu Arg Gly Leu Asn Pro Cys
              295
GAG GTT GGC ACG GAC TGA CTCCGTGGGC CGCTGCCCTT CCTCTCCTGA 3225
Glu Val Gly Thr Asp
              310
TGAGTCACAG GCTGCGGTGG GCGTGCGGT CCTGGTGGGG CCGTGCGGTG AGGGCCRCGC 3285
GCTGGGAGCC GCRTGCCCTG GGGCCAGKCC TGACCCCTGGT ACCGAAGCTG TGGACGTTCT 3345
CGCCACACTC AACCCCATGA GCTTCCAGCC AAGGATGCCC TGGCCGATTG GAAATGCTGT 3405
AAAAATGCAAA CTAAGTTATT ATATTTTTTT TTGGTAAAAA AGAAATGTCC ATAGGAAACA 3465
AATTCYGTG TCTTAAACG CCTTGGTGTG CCGTCTGATA CTGTTCTCTA AAGACGTTAG 3525
GAGTCACGGC ATCTGGCCTG CCGTTGGGTG AAGCACTGGC CGTTGGGCAC AGTGGATGTG 3585
TGAAAAGGTG CCATTCAGAG TTGTTATTCT CATGACGGAA GTTTTGGAGC CAAATAATAC 3645
GTTTTTTTAT TTCATTTTAT TTTTAAAGGA TGAGCTTTGG TCCTTTTCAG GCCGCCGGTT 3705
GTTTCCGTTT CCGAGAATAA AGACGAGGAT CCGACC 3741

```

Figure 1 (cont 3)

GGAGC ATG CCG GGC GCG GCG GCG GCG GCA TGG GGG GCG GCG GCG CAG CCG 50
 MET Arg Gly Ala Ala Arg Ala Ala Trp Gly Arg Ala Gly Gln Pro 15
 TGG CCG CGA CCC CCG GCG GCG GCG GCG GCG CCG CCG CTC CCG CTG 15
 Trp Pro Arg Pro Pro Ala Pro Gly Pro Pro Pro Pro Pro Leu Pro Leu 30
 CTG CTC CTG CTC CCG GCG GCG GCG GCG GCG GCG GCG GCG CAG TAC 30
 Leu Leu Leu Leu Ala Ala Gly Leu Leu Gly Ala Gly Ala Gln Tyr 45
 TCC AGC GAC CCG TGC AGC TGG AAG GCG AGC GCG CTG ACG CAC GAG GCA 45
 Ser Ser Asp Arg Cys Ser Trp Lys Gly Ser Gly Leu Thr His Glu Ala 60
 CAC AGG AAG GAG GTG GAG GAG CAG GTG TAT CTG CCG TGT GCG GCG GGT GCC 60
 His Arg Lys Glu Val Val Gln Val Tyr Leu Arg Cys Ala Ala Gly Ala 75
 GTG GAG TGG ATG TAC CCA ACA GGT GCT CTC ATC GGT AAC CTG CCG CCC 75
 Val Glu Trp MET Tyr Pro Thr Gly Ala Leu Ile Val Asn Leu Arg Pro 90
 AAC ACC TTC TCG CCT GCC CCG CAC CTG ACC GTG TGC ATC AGG TCC TTC 90
 Asn Thr Phe Ser Pro Ala Arg His Leu Thr Val Cys Ile Arg Ser Phe 110
 ACC GAC TCC TCG GCG GCG AAT ATT TAT TTG GAA AAA ACT GGA GAA CTG 110
 Thr Asp Ser Ser Gly Ala Asn Ile Tyr Leu Glu Lys Thr Gly Glu Leu 125
 AGA CTG CTG GTA CCG GAC GCG GCG GCG AGG CCC GCG GCG GTG CAG TGT 125
 Arg Leu Leu Val Pro Asp Gly Asp Gly Arg Pro Gly Arg Val Gln Cys 140
 130 135 140

Figure 2

TTT GGC CTG GAG CAG GGC GGC CTG TTC GTG GAG GCC ACC CCG CAG CAG CAG 482
 Phe Gly Leu Glu Glu Gln Gly Gly Leu Phe Val 145
 GAT ATC GGC CGG AGG ACC ACA GGC TTC CAG TAC GAG CTG GAG GGT AGG AGG 530
 Asp Ile Gly Arg Arg Thr Thr Gly Gly Phe Gln Tyr Glu Leu Val Arg Arg 175
 160 CAC AGG GCG TCG GAC CAG CAC GAG CTG TCT GCG CCG TGC CGT CCC TGC
 His Arg Ala Ser Asp Leu His Glu Leu Ser Ala Pro Cys Arg Pro Cys 190
 180 AGT GAC ACC GAG GTG CTC CTA GCC GTC TGC ACC AGC GAC TTC GCC GTT
 Ser Asp Thr Glu Val Leu Leu Ala Val Cys Thr Ser Asp Phe Ala Val 205
 195 CGA GGC TCC ATC CAG CAA GTT ACC CAC GAG CCT GAG CCG CAG GAC TCA
 Arg Gly Ser Ile Gln Gln Val Thr His Glu Pro Glu Arg Gln Asp Ser 220
 210 GCC ATC CAC CTG CGC GTG AGC AGA CTC TAT CGG CAG AAA AGC AGG GTC
 Ala Ile His Leu Arg Val Ser Arg Leu Tyr Arg Gln Lys Ser Arg Val 235
 225 TTC GAG CCG GTG CCC GAG GGT GAC GGC CAC TGG CAG GGG CGC GTC AGG
 Phe Glu Pro Val Pro Glu Gly Asp Gly His Trp Gln Gly Arg Val Arg 255
 240 ACG CTG CTG GAG TGT GGC GTG CCG CCG GGG CAT GGC GAC TTC CTC TTC
 Thr Leu Leu Glu Cys Gly Val Arg Pro Gly His Gly Asp Phe Leu Phe 265
 270 ACT GGC CAC ATG CAC TTC GGC GAG GCG CGG CTC GGC TGT GCC CCA CGC
 Thr Gly His MET His Phe Gly Glu Ala Arg Leu Gly Cys Ala Pro Arg 285
 290 TTC AAG GAC TTC CAG AGG ATG TAC AGG GAT GCC CAG GAG AGG GGG CTG
 Phe Lys Asp Phe Gln Arg MET Tyr Arg Asp Ala Gln Glu Arg Gly Leu 300
 305 AAC CCT TGT GAG GTT GGC ACG GAC TGA CTCCGTGGC CGCTGCCCTT
 Asn Pro Cys Glu Val Gly Thr Asp 310

CCTCTCCTGA	TGAGTCACAG	GCTGCGGTGG	GCGTGCGGT	CCTGGTGGG	CCGTGCGGTG	1021
AGGCCACGC	GCTGGGAGCC	GCGTGCCCTG	GGCCAGTCC	TGACCCCTGGT	ACCGAAGCTG	1081
TGGACGTTCT	CGCCACACTC	AACCCCATGA	GCTTCCAGCC	AAGGATGCCC	TGGCCGATTG	1141
GAAATGCTGT	AAAATGCCAA	CTAAGTTATT	ATATTTT	TTGGTAAAAA	AGAAATGTCC	1201
ATAGGAAACA	AATTCCTGTG	TCTTAAACG	CCTTGGTGTG	CCGTCTGATA	CTGTTCTCTA	1261
AAGACGTTAG	GAGTCACGGC	ATCTGGCCTG	CGTTGGGTG	AAGCACTGGC	CGTTGGGCAC	1321
AGTGGATGTG	TGAAAAGGTG	CCATTCAAG	TTGTTATTCT	CATGACGGAA	GTTTGGGAGC	1381
CAAAATAATAC	GTTTTTTATT	TTCATTTTAT	TTTTAAAGGA	TGAGCTTTGG	TCCTTTTCAG	1441
GCCGCCGGTT	GTTCCTCGTTC	CCGAGAAATA	AGACGAGGAT	CCGACC		1487


Figure 2 (con't 2)

GCAGCCGGCG	CGCTTCTCTA	GTTCAGCCTT	GGCGGGCTCC	TGTGTTGGGC	GGCTAGGGGC	60
GAGCCGGGAT	GGGCTATAGA	CGCGGACGT	GATCAGTTCC	CACGCGGACC	CACGCCCTCCC	120
ATCGCTCTGC	CTCAAGAGCC	TATTCTGTGG	GTGCAGGCAC	GCACCGGACG	CAGACCCGGC	180
CGGAGC	ATG CCG GGT GCG GTG TGG GCG GCC CCG AGG CCG GCG GCG CAG					228
	MET Arg Gly Ala Val Trp Ala Ala Arg Arg Arg Ala Gly Gln					
		5	10			
CAG TGG CCT CCG TCC CCG GGC CCT GGC CCG GGT CCG CCC CCG CCG CCA						276
Gln Trp Pro Arg Ser Pro Gly Pro Gly Pro Gly Pro Pro Pro Pro						
	15	20	25	30		
CCG CTG CTG TTG CTG CTA CTA CTG CTG CTG GGC GGC GCG AGC GCT CAG						324
Pro Leu Leu Leu Leu Leu Leu Leu Leu Leu Gly Ala Ser Ala Gln						
	35	40	45			
TAC TCC AGC GAC CTG TGC AGC TGG AAG GGC AGT GGG CTC ACC CGA GAG						372
Tyr Ser Ser Asp Leu Cys Ser Trp Lys Gly Ser Gly Leu Thr Arg Glu						
	50	55	60			
GCA CGC AGC AAG GAG GTG GAG CAG GTG TAC CTG CCG TGC TCC GCA GGC						420
Ala Arg Ser Lys Glu Val Glu Gln Val Tyr Leu Arg Cys Ser Ala Gly						
	65	70	75			
TCT GTG GAG TGG ATG TAC CCA ACT GGC GCG CTC ATT GTT AAC CTA CGG						468
Ser Val Glu Trp MET Tyr Pro Thr Gly Ala Leu Ile Val Asn Leu Arg						
	80	85	90			
CCC AAC ACC TTC TCA CCT GCC CAG AAC TTG ACT GTG TGC ATC AAG CCT						516
Pro Asn Thr Phe Ser Pro Ala Gln Asn Leu Thr Val Cys Ile Lys Pro						
	95	100	105			
TTC AGG GAC TCC TCT GGA GCC AAT ATT TAT TTG GAA AAA ACT GGA GAA						564
Phe Arg Asp Ser Ser Gly Ala Asn Ile Tyr Leu Glu Lys Thr Gly Glu						
	115	120	125			
CTA AGA CTG TTG GTG CGG GAC ATC AGA GGT GAG CCT GGC CAA GTG CAG						612
Leu Arg Leu Leu Val Arg Asp Ile Arg Gly Glu Pro Gly Gln Val Gln						
	130	135	140			

Figure 3

TGC TTC AGC CTG GAG CAG GGA GGC TTA TTT GTG GAG GCG ACA CCC CAA 660
 Cys Phe Ser Leu Glu Gln Gly Gly Leu Phe Val Glu Ala Thr Pro Gln
 145
 CAG GAC ATC AGC AGA AGG ACC ACA GGC TTC CAG TAT GAG CTG ATG AGT 708
 Gln Asp Ile Ser Arg Arg Thr Thr Gly Phe Gln Tyr Glu Leu MET Ser
 160
 GGG CAG AGG GGA CTG GAC CTG CAC GTG CTG TCT GCC CCC TGT CGG CCT 756
 Gly Gln Arg Gly Leu Asp Leu His Val Leu Ser Ala Pro Cys Arg Pro
 175
 TGC AGT GAC ACT GAG GTC CTC CTT GCC ATC TGT ACC AGT GAC TTT GTT 804
 Cys Ser Asp Thr Glu Val Leu Leu Ala Ile Cys Thr Ser Asp Phe Val
 180
 GTC CGA GGC TTC ATT GAG GAC GTC ACA CAT GTA CCA GAA CAG CAA GTG 852
 Val Arg Gly Phe Ile Glu Asp Val Thr His Val Pro Glu Gln Val
 210
 TCA GTC ATC TAC CTG CGG GTG AAC AGG CTT CAC AGG CAG AAG AGC AGG 900
 Ser Val Ile Tyr Leu Arg Val Asn Arg Leu His Arg Gln Lys Ser Arg
 225
 GTC TTC CAG CCA GCT CCT GAG GAC AGT GGC CAC TGG CTG GGC CAT GTC 948
 Val Phe Gln Pro Ala Pro Glu Asp Ser Gly His Trp Leu Gly His Val
 240
 ACA ACA CTG CTG CAG TGT GGA GTA CGA CCA GGC CAT GGG GAA TTC CTC 996
 Thr Thr Leu Leu Gln Cys Gly Val Arg Pro Gly His Gly Glu Phe Leu
 255
 TTC ACT GGA CAT GTG CAC TTT GGG GAG GCA CAA CTT GGA TGT GCC CCA 1044
 Phe Thr Gly His Val His Phe Gly Glu Ala Gln Leu Gly Cys Ala Pro
 275
 CGC TTT AGT GAC TTT CAA AGG ATG TAC AGG AAA GCA GAA GAA ATG GGC 1092
 Arg Phe Ser Asp Phe Gln Arg MET Tyr Arg Lys Ala Glu Glu MET Gly
 290
 ATA AAC CCC TGT GAA ATC AAT ATG GAG TGA CTGCAGGGT GACACAGTAC 1142
 Ile Asn Pro Cys Glu Ile Asn MET Glu
 305
 310
 TGTGTGTCCTT CAGATGAGCC ATGTTTGTG GGCTCAGTCG CTCTATCATA TCCTGATAGA 1202
 GATTGCAGAC TGGTGGCATG GGCCAGCCT GGTGCTAGAA CTGGGAAGGT ACATGCTGCT 1262
 CTGACCCCTT AGGTCCACG CAAGGATGCC CTGACCCATT GGAACCTGCTG TAAATGCAA 1322
 ACTAAGTTAT TATATTTTTT TTGTAAAAGA AAAAAAAAAA 1362

Figure 3 (cont'd 1)

Figure 4

human	Met	Arg	Gly	Ala	Ala	Arg	Ala	Ala	Trp	Gly	Arg	Ala	Gly	Gln	Pro	15
mouse	Met	Arg	Gly	Ala	Val	Trp	Ala	Ala	Arg	Arg	Arg	Ala	Gly	Gln	Gln	15
human	Trp	Pro	Arg	Pro	Pro	Ala	Pro	Gly	Pro	Pro	Pro	Pro	Pro	Pro	Leu	30
mouse	Trp	Pro	Arg	Ser	Pro	Gly	Pro	Gly	Pro	Gly	Pro	Pro	Pro	Pro	Pro	30
human	Leu	Leu	Leu	Leu	Leu	Leu	Ala	Gly	Leu	Leu	Gly	Gly	Ala	Gly	Ala	45
mouse	Pro	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Gly	Gly	Ala	Ser	Ala		45
human	Gln	Tyr	Ser	Ser	Asp	Arg	Cys	Ser	Trp	Lys	Gly	Ser	Gly	Leu	Thr	60
mouse	Gln	Tyr	Ser	Ser	Asp	Leu	Cys	Ser	Trp	Lys	Gly	Ser	Gly	Leu	Thr	60
human	His	Glu	Ala	His	Arg	Lys	Glu	Val	Glu	Gln	Val	Tyr	Leu	Arg	Cys	75
mouse	Arg	Glu	Ala	Arg	Ser	Lys	Glu	Val	Glu	Gln	Val	Tyr	Leu	Arg	Cys	75

Figure 5

human	Ala	Ala	Gly	Ala	Val	Glu	Trp	Met	Tyr	Pro	Thr	Gly	Ala	Leu	Ile	90
mouse	Ser	Ala	Gly	Ser	Val	Glu	Trp	Met	Tyr	Pro	Thr	Gly	Ala	Leu	Ile	90
human	Val	Asn	Leu	Arg	Pro	Asn	Thr	Phe	Ser	Pro	Ala	Arg	His	Leu	Thr	105
mouse	Val	Asn	Leu	Arg	Pro	Asn	Thr	Phe	Ser	Pro	Ala	Gln	Asn	Leu	Thr	105
human	Val	Cys	Ile	Arg	Ser	Phe	Thr	Asp	Ser	Ser	Gly	Ala	Asn	Ile	Tyr	120
mouse	Val	Cys	Ile	Lys	Pro	Phe	Arg	Asp	Ser	Ser	Gly	Ala	Asn	Ile	Tyr	120
human	Leu	Glu	Lys	Thr	Gly	Glu	Leu	Arg	Leu	Leu	Val	Pro	Asp	Gly	Asp	135
mouse	Leu	Glu	Lys	Thr	Gly	Glu	Leu	Arg	Leu	Leu	Val	Arg	Asp	Ile	Arg	135
human	Gly	Arg	Pro	Gly	Arg	Val	Gln	Cys	Phe	Gly	Leu	Glu	Gln	Gly	Gly	150
mouse	Gly	Glu	Pro	Gly	Gln	Val	Gln	Cys	Phe	Ser	Leu	Glu	Gln	Gly	Gly	150
human	Leu	Phe	Val	Glu	Ala	Thr	Pro	Gln	Gln	Asp	Ile	Gly	Arg	Arg	Thr	165
mouse	Leu	Phe	Val	Glu	Ala	Thr	Pro	Gln	Gln	Asp	Ile	Ser	Arg	Arg	Thr	165

Figure 5 (con't 1)

human	Thr	Gly	Phe	Gln	Tyr	Glu	Leu	Val	Arg	Arg	His	Arg	Ala	Ser	Asp	180
mouse	Thr	Gly	Phe	Gln	Tyr	Glu	Leu	Met	Ser	Gly	Gln	Arg	Gly	Leu	Asp	180
human	Leu	His	Glu	Leu	Ser	Ala	Pro	Cys	Arg	Pro	Cys	Ser	Asp	Thr	Glu	195
mouse	Leu	His	Val	Leu	Ser	Ala	Pro	Cys	Arg	Pro	Cys	Ser	Asp	Thr	Glu	195
human	Val	Leu	Leu	Ala	Val	Cys	Thr	Ser	Asp	Phe	Ala	Val	Arg	Gly	Ser	210
mouse	Val	Leu	Leu	Ala	Ile	Cys	Thr	Ser	Asp	Phe	Val	Val	Arg	Gly	Phe	210
human	Ile	Gln	Gln	Val	Thr	His	Glu	Pro	Glu	Arg	Gln	Asp	Ser	Ala	Ile	225
mouse	Ile	Glu	Asp	Val	Thr	His	Val	Pro	Glu	Gln	Gln	Val	Ser	Val	Ile	225
human	His	Leu	Arg	Val	Ser	Arg	Leu	Tyr	Arg	Gln	Lys	Ser	Arg	Val	Phe	240
mouse	Tyr	Leu	Arg	Val	Asn	Arg	Leu	His	Arg	Gln	Lys	Ser	Arg	Val	Phe	240
human	Glu	Pro	Val	Pro	Glu	Gly	Asp	Gly	His	Trp	Gln	Gly	Arg	Val	Arg	255
mouse	Gln	Pro	Ala	Pro	Glu	Asp	Ser	Gly	His	Trp	Leu	Gly	His	Val	Thr	255
human	Thr	Leu	Leu	Glu	Cys	Gly	Val	Arg	Pro	Gly	His	Gly	Asp	Phe	Leu	270
mouse	Thr	Leu	Leu	Gln	Cys	Gly	Val	Arg	Pro	Gly	His	Gly	Glu	Phe	Leu	270
human	Phe	Thr	Gly	His	Met	His	Phe	Gly	Glu	Ala	Arg	Leu	Gly	Cys	Ala	285
mouse	Phe	Thr	Gly	His	Val	His	Phe	Gly	Glu	Ala	Gln	Leu	Gly	Cys	Ala	285
human	Pro	Arg	Phe	Lys	Asp	Phe	Gln	Arg	Met	Tyr	Arg	Asp	Ala	Gln	Glu	300
mouse	Pro	Arg	Phe	Ser	Asp	Phe	Gln	Arg	Met	Tyr	Arg	Lys	Ala	Glu	Glu	300
human	Arg	Gly	Leu	Asn	Pro	Cys	Glu	Val	Gly	Thr	Asp					311
mouse	Met	Gly	Ile	Asn	Pro	Cys	Glu	Ile	Asn	Met	Glu					311

Figure 5 (con't 2)




Figure 6a




Figure 6b

16/34





Figure 7



mTNF(AA pos 81 to 103)

ATG GTA AGA TCA AGT AGT CAA AAT TCG AGT GAC AAG CCT GTA GCC CAC
Met Val Arg Ser Ser Ser Gln Asn Ser Ser Asp Lys Pro Val Ala His

EcoRI

GTC GTA GCA AAC CAC CAA GTG GAG GAG CAG GGA ATT CAC CAT CAC CAT
Val Val Ala Asn His Gln Val Glu Glu Gln Gly Ile His His His His

BprPI		ApaI					
Dra III	BamHI	SmaI	NcoI	BspMII	StuI		
CAC CAC GTG	GAT CCC GGG CCC	ATG GCT	TTC CGG AGG	CCT			
His His Val	Asp Pro Gly Pro	Met Ala	Phe Arg Arg	Pro			
	formic acid	CnBr	kallikrein	protease VII			

Figure 8a

AATTCCGGGG ATCTCTCACC TACCAAAACAA TGCCCCCCTG CAAAAAATAA ATTCAATATAA 60
 AAAACATACA GATAAACCATC TGCGGTGATA AATTATCTCT GGCGGTGTG ACATAAATAC 120
 CACTGGCGGT GATACTGAGC ACATCAGCAG GACGCACTGA CCACCATGAA GGTGACGCTC 180
 TTAATAAATA AGCCCTGAAG AAGGCGAGGG GTACCAGGAG GTTTAAATCA TGGTAAGATC 240
 AAGTAGTCAA AATTGAGTG AATTGAGTG ACAAAGCTGT AGCCACGTC GTAGCAAACC ACCAAGTGGA 300
 GGAGCAGGGA ATTCACCATC ATTCACCATC ACCATCACCA CGTGGATCCC GGGCCCATGG CTTTCCGGAG 360
 GCCTCTAGAG TCGACCGGCA ATGCCCAAGC TTGGCTGTTT TGCGGGATGA GAGAAAGATT TCAGCCTGAT 420
 ATTTTITTTG ATGCCCAAGC TGCAAGCTTA AGTAAGTAAG CCGCCAGTTC CGCTGGCGGC 480
 ACAGATTAAA TCAGAACGCA GAAGCGGTCT GATAAAACAG AATTGCGCTG GCGGCAGTAG 540
 CGCGGTGGTC CCACCTGACC CCATGCCGAA CTCAGAAAGTG AAACGCCGTA GCGCCGATGG 600
 TAGTGTGGGG TCTCCCCATG CGAGAGTAGG GAACTGCCAG GCATCAATA AAACGAAAGG 660
 CTCAGTCGAA AGACTGGGC TTTCGTTTTA TCTGTTGTTT GTCGGTGAAC GCTCTCCTGA 720
 GTAGGACAAA TCCGCCGGGA GCGGATTTGA ACGTTGCGAA GCAACGGCCC GGAGGTGGC 780
 GGCAGGACG CCGGCCATAA ACTGCCAGGC ATCAAAATTA GCAGAAAGCC ATCCTGACGG 840
 ATGGCCTTTT TGCGTTTCTA CAAACTCTTT TGTTTATTTT TCTAAATACA TTCAAATATG 900
 TATCCGCTCA TGAGACAATA ACCCTGATAA ATGCTTCAAT AATAAAAGGA TCTAGGTGAA 960
 GATCCTTTT GATAATCTCA TGACCAAAT CCCTTAACGT GAGTTTTCGT TCCACTGAGC 1020
 GTCAGACCCC GTAGAAAGA TCAAAGGATC TTCTTGAGAT CCTTTTTC TCGCGGTAAT 1080
 CTGCTGCTG CAAACAAAA AACCAACGCT ACCAGCGGTG GTTTGTTTGC CGGATCAAGA 1140
 GCTACCAACT CTTTTTCCGA AGGTAACCTGG CTTCAGCAGA GCGCAGATAC CAAATACATG 1200
 CCTTCTAGTG TAGCCGTAGT TAGGCCACCA CTTCAAGAAC TCTGTAGCAC CGCCTACATA 1260
 CCTCGCTCTG CTAATCCTGT TACCACTGGC TAAGGCGCAG CCGTCGGGT GAAACGGGGG 1320
 CCGGTGGAC TCAAGACGAT AGTTACCGGA TGGAGCGAAC GACCTACACC GAACGAGGG 1380
 TGAGCATTGA GAAAGCGCA CGCTTCCCGA AGGAGAAAG GCGGACAGGT ATCCGGTAAG 1440
 CGCAGGGTC GGAACAGGAG AGCGCACGAG AGGAGCTTCA GGGGAAACG CCTGGTATCT 1500
 TTATAGTCCT GTCCGGTTTC GCCACCTCTG ACTTGAGCGT CGATTTTTGT GATGCTCGTC 1560
 AGGGGGCGG AGCCTATGGA AAAACGCCAG CAACGCGGC TTTTACGGT TCCTGGCCCTT 1620
 TTGCTGGCCT TTTGCTCACA TGTTCTTTCC TGCGTTATCC CCTGATCTG TGGATAACCG 1680
 TATTACCGCC TTTGAGTGAG CTGATACCGC TCGCCGCGAG CGAACGACCG AGCGCAGCGA 1740
 GTCAGTGAGC GAGGAAGCGG AAGAGCGCTG ACTTCCCGCT TTCCAGACTT TACGAAACAC 1800
 GGAAACCGAA GACCATTCAT GTTGTGCTC AGGTCGCGA CGTTTTCAG CAGCAGTCGC 1860
 TTCACGTTCC CTCGCGTATC GGTGATTCTAT TCTGCTAAC AGTAAGGCAA CCGCGCCAGC 1920
 CTAGCCGGGT CCTCAACGAC AGGAGCACGA TCATGCGCAC CCGTGGCCAG GACCCACGC 1980
 TGCCCGAGAT GCGCCGCGTG CCGCTGCTGG AGATGGCGGA GCGGATGGAT ATGTTCTGCC 2040
 AAGGGTTGGT TTGCGCATTC ACAGTTCTCC GCAAGATTG ATTGGCTCCA ATTCTTGGAG 2100
 TGGTGAATCC GTTAGCGAGG TGCCGCCCGC TTCCATTTCAG GTCGAGGTGG CCCGGCTCCA 2220

Figure 8b

TGCACCGCGA CGCAACGCGG GGAGGCAGAC AAGTATAGG GCGGCGCCTA CAATCCATGC 2280
 CAACCCGTTT CATGTGCTCG CCGAGGCGGC ATAAATCGCC GTGACGATCA GCGGTCCAGT 2340
 GATCGAAGTT AGGCTGGTAA GAGCCGCGAG CGATCCTTGA AGCTGTCCCT GATGGTCGTC 2400
 ATCTACCTGC CTGGACAGCA TGGCCTGCAA CGCGGGCATC CCGATGCCGC CGGAAGCGAG 2460
 AAGAATCATA ATGGGAAGG CCATCCAGCC TCGCGTCGCG AACGCCAGCA AGACGTAGCC 2520
 CAGCGCGTCG GCGGCCATGC CGGCGATAAT GGCTGTCTTC TCGCCGAAAC GTTGTGGTGGC 2580
 GGGACCAAGT ACGAAGGCTT GAGCGAGGGC GTCCCTCGCCG AAAATGACCC AGAGCGCTGC 2640
 GCCGATCATC GTCGCGCTCC AGCGAAAGCG GCATGATAAA GAAGACAGTC ATAAGTGCGG CGACGATAGT 2700
 CGGCACCTGT CCTACGAGTT GCGCACCGGA AGGAGCTGAC TGGGTTGAAG GCTCTCAAGG GCATCGGTGC 2760
 CATGCTCTCC TTATGCGACT CCTGCATTAG GAAGCAGCCC AGTAGTAGGT TGAGGCCGTT 2820
 ACGCTCTCCC GCGCAAGGA ATGGTGATG CACGCCGAA ACAAGCGCTC ATGAGCCCCG GTCCCCCGGC 2880
 GAGCACCGCC GCCACCATAC CCACGCCGAT ATAGGCGCCA GCAACCCGAC CTGTGGCGGC 2940
 CACGGGGCCT GCCACCATAC CCACGCCGAT ATAGGCGCCA GCAACCCGAC CTGTGGCGGC 3000
 CCGATCTTCC CCATCGGTGA TGTGCGCGAT ATAGGCGCCA GCAACCCGAC CTGTGGCGGC 3060
 GGTGATGCCG GCCACGATGC GTCCGGCGTA GAGGATCCAC AGGACGGGTG TGGTCGCCAT 3120
 GATCGCGTAG TCGATAGTGG CTCCAAGTAG CGAAGCGAGC AGGACTGGGC GCGGGCCAAA 3180
 GCGSTCGGAC AGTGCTCCGA GAACGGGTGC GCATAGAAAT TGCATCAACG CATATAGCGC 3240
 TAGCAGCACG CCATAGTGAC TGGCGATGCT GTCGGAATGG ACGATATCCC GCAAGAGGCC 3300
 CGGCAGTACC GGCATAACCA AGCCTATGCC TACAGCATCC AGGGTGACGG TGCCGAGGAT 3360
 GACGATGAGC GCATTGTTAG ATTTTCATACA CCGTGCCTGA CTGCGTTAGC AATTAACTG 3420
 TGATAAACTA CCGCATTAAG GCTTATCGAT GATAAGCTGT CAAACATGAG AATT 3474

Figure 8b (con't 1)

20/34




Figure 9




Figure 10

22/34





Figure 11

Figure 12

24/34




Figure 13

25/34




Figure 14

26/34




Figure 15

27/34




Figure 16

28/34




Figure 17

29/34




Figure 18

30/34




Figure 19

THYMOCYTE-ASSAY




Figure 20




Figure 21a




Figure 21b




Figure 22

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)⁹

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 C12N15/19; C12P21/02; A61K37/02; C12N15/11
 C07K13/00; C12N15/00; C12P21/08; A01K67/027

II. FIELDS SEARCHEDMinimum Documentation Searched⁷

Classification System

Classification Symbols

Int.Cl. 5 C07K ; C12N ; C12P

Documentation Searched other than Minimum Documentation
 to the Extent that such Documents are Included in the Fields Searched⁸

III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
------------------------	--	-------------------------------------

A

EP,A,0 310 056 (SHIONOGI SEIYAKU KABUSHIKI
 KAISHA)
 5 April 1989

¹⁰ Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

20 AUGUST 1993

Date of Mailing of this International Search Report

02 -09- 1993

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

LE CORNEC N.D.R.

EP 9301022
SA 73402

20/08/93

EPO FORM 10479

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

